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Abstract
Hypofractionated radiotherapy is currently a clinical area of research. Clinical trials
are looking into giving larger doses of ionizing radiation per fraction, by using fewer
fractions. The goal is to prove that the tumor can be better controlled in this way or
that the treatment time can be shortened with the same or better clinical outcome.
However for moving tumors large safety margins need to be applied to cover the tu-
mor with the full dose. This leads to a large amount of healthy tissue irradiated with
high doses and eventually increases side effects. To savely apply hypofractionated
treatments to moving structures, motion management techniques are needed. Two
approaches to reduce intrafractional motion of moving tumors to be able to increase
the dose per fraction are implemented and evaluated within the frame of this thesis.
On the one hand with the introduction of the flattening filter free (FFF) technique,
a reduction in treatment time was achieved which led to excellent stability of the
patients during treatment. On the other hand a prototype system was developed to
compensate respiratory motion.
In a first step two FFF beams with nominal energy 6 MV (X6FFF) and 10 MV
(X10FFF) were commissioned. These beams allow a maximum dose rate of up to
24 Gy per minute (X10FFF in depth of maximum dose, a source-surface distance
of 100 cm and a field size of 10x10 cm2), leading to shortened treatment times and
eventually reduced target movement. A prerequisite for the characterisation of FFF
radiation beams is the knowledge of the behaviour of detectors in the high dose
per pulse FFF beams. Therefore a study was performed evaluating seven widely
used ionization chambers. For flattened beams, the ion collection efficiency of all
air-vented ionization chambers (except for the pinpoint chamber) was above 0.995.
By removing the flattening filter a reduction in collection efficiency was found of ap-
proximately 0.5-0.9% for a 10 MV beam (X10). Using the liquid ionization chamber
the ion collection efficiency for flattened beams was above 0.990 for all dose rates.
However, this chamber showed a low collection efficiency of 0.940 for the X10FFF
beam at a dose rate of 31.9 Gy/min. All investigated air-vented ionization chambers
can be reliably used for relative dosimetry of FFF beams. Due to their increased
saturation in high dose rate FFF beams, liquid ionization chambers appear to be
unsuitable for dosimetry within this context.
In the next step a planning study was performed, evaluating FFF beams for hy-
pofractionated prostate cancer. FFF beams have a larger dose rate on the central
axis than flattened beams, an increased surface dose and a reduced beam quality
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factor. Therefore the planning study evaluated the use of FFF beams for patient
treatments and the capability of the planning system to optimize the FFF beams.
Dose distributions, out-of field doses and treatment times were evaluated. Volu-
metric modulated arc therapy (VMAT) treatment planning was performed for seven
patients with prostate cancer using TrueBeam linear accelerator and photon beams
with (X6, X10) and without (X6FFF, X10FFF) flattening filter. No difference was
detected in PTV coverage, conformity and homogeneity among the four beams.
Mean body dose and body volume receiving 50% of the prescribed dose decreased
with increasing mean energy (R2 = 0.8275, p < 0.01). There was a significant in-
crease in the mean dose to the rectum for the X10 compared to X6 (2.6%, p <
0.01). Mean dose to the bladder increased by 1.3% for X6FFF and decreased by
2.3% for X10FFF. Therefore it was concluded, that X10FFF beam provided the
best solution, sparing rectum and bladder and minimizing whole body dose. Using
a single arc and FFF, treatment time was reduced by 35% (2SD = 10%) compared
to a flattened beam (Dose per fraction 3 Gy).
After verifying the planning system, the capability of the linear accelerator to deliver
the high dose rate beams was investigated. There are concerns regarding the safe
delivery of FFF beams, especially regarding the monitor chamber, which is used
to steer the beam. Additionally the increased output of TrueBeam places higher
demands on the reaction time of the servo system as well as the control system of
the linear accelerator. Pre-treatment quality assurance (QA) data from 4 centers
were analysed with different verification devices to assess reliability and dosimetric
accuracy of FFF beam delivery for intensity modulated radiotherapy (IMRT) and
VMAT techniques. Gamma evaluation was performed with a dose difference of 3%
and a distance to agreement of 3 mm scoring the gamma agreement index (GAI, %
of field area passing the test). 224 patients with 1–6 lesions in various anatomical
regions and dose per fraction ranging from 1.8 Gy to 25 Gy were included in the
study; 88 were treated with X6FFF beam and 136 with X10FFF beam. Gafchromic
films in solid water, air-vented chambers, DELTA4 phantom, ARCCHECK phantom
or MATRIXX phantom were used to verify the dose distributions. Dose calculation
as well as dose delivery was equally accurate for IMRT and VMAT delivery (IMRT:
GAI = 99.3% (1SD = 1.1%); VMAT: GAI=98.8% (1SD = 1.1%)) as well as for the
two beams evaluated (X6FFF: GAI = 99.1% (1SD = 1.0%); X10FFF: GAI=98.8%
(1SD = 1.2%)). Based on the high GAI scores of all verified plans, it was concluded
that the TrueBeam FFF modality, analyzed with a variety of verification devices
and planned with Eclipse planning system is dosimetrically accurate (within the
specified limits 3mm/3%) for both X6FFF and X10FFF beam energies.
Due to the high available dose rate FFF beams are often considered for hypo-
fractionated treatments of breast, lung and prostate cancer. The clinical efficiency
and accuracy benefit of FFF beams for extra-cranial lesions was evaluated. The in-
ternal target volume (ITV) concept was used to treat 16 patients with lung tumors
and 10 patients with abdominal tumors. ITV to planning target volume (PTV)
margins were calculated according to the Van Herk Formula and tumor stability
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was determined for the short treatment times of FFF beams. Beam-on time was on
average 1.6 min (1SD = 0.6 min), with the recorded total treatment times of 18.5
min (1SD = 3.5 min). The time advantage of using FFF beams was dose-dependent
and started at 4 Gy for X6FFF and at 10 Gy for X10FFF beams. The average of the
tumor displacements during treatment was 2.0 mm (1SD = 1.0 mm). This showed
that stereotactic body radiotherapy (SBRT) using FFF beams is time efficient and
associated with excellent patient stability. According to Van Herk’s formula, ITV
to PTV margins of 6 mm are sufficient in our patient cohort. Further studies are
necessary to assess clinical outcome and toxicity.
It was shown by several authors that prostate as well as patient motion increases
with increased treatment time. The use of flattening filter free beams has the poten-
tial to reduce motion of the patient as well as prostate motion, however for periodic
respiratory motion there is no benefit expected. In the second part of the thesis
the reduction of safety margins for respiratory motion was addressed. A treatment
couch tracking system to counter steer respiratory tumor motion was developed and
implemented. Three different motion detection sensors with different lag times were
evaluated: the topometrical system Topos, the respiratory gating system RPM and a
laser sensor. The control system was implemented in the block diagram environment
Simulink. To achieve real time performance the Simulink models were executed on
a real time engine, provided by Real-Time Windows Target. To achieve high con-
trol performance with good reference tracking and good disturbance rejection, a
proportional-integral control system was implemented. The geometrical accuracy of
the system was evaluated by measuring the mean deviation to the reference position
(static position) during motion tracking. A hexapod system was moving according
to seven respiration patterns previously acquired with the RPM system as well as
according to a sin6 function with two different frequencies (0.33 Hz and 0.17 Hz).
The treatment table Protura compensated the motion. It was found that short delay
times are needed to be able to track all the respiration frequencies. The laser based
tracking system with the small lag time of 60 ms could track all the respiration
patterns. An increase in delay time from 60 ms (Laser based system) to 130 ms
(RPM based system) resulted in a non-sufficient tracking performance for the sin6
pattern (frequency 0.33 Hz). The system with the largest lag time of 300 ms was
only able to track four of the respiration patterns. For the four patient respiration
patterns, which could be tracked by all three systems, a mean absolute deviation of
0.19 mm was achieved using the laser sensor, 0.45 mm using the RPM system and
0.52 mm using the TOPOS system. More scientific work is necessary to extend our
prototype to tracking of internal motion
With the development of the couch tracking system, a second approach to reduce
intra-fractional motion was implemented and evaluated. In the future we want to
combine the fast treatments with FFF beams and the active motion compensation
with the tracking system in order to optimally treat the patients.
Zusammenfassung
Die hypofraktionierte Strahlentherapie, dh die Therapie wird in wenige Fraktionen
mit hohen Einzeldosen durchgefu¨hrt, hat sowohl in vor-klinischen als auch in ersten
klinischen Studien gute Resultate gezeigt. Deshalb gibt es im Moment eine grosse
Anzahl klinischer Studien die zeigen sollen, dass eine hypofraktionierte Bestrahlung
zu einer besseren Tumorkontrolle fu¨hrt. Jedoch sind die Bestrahlungen mit ho-
hen Einzeldosen problematisch fu¨r bewegliche Tumore. Damit der Tumor genu¨gend
Dosis bekommt, muss der ganze Bewegungsbereich des Tumors bestrahlt werden.
Dadurch wird auch viel gesundes Gewebe mit einer therapeutischen Dosis bestrahlt,
was zu sta¨rkeren Nebenwirkungen fu¨hren kann. Dieser Umstand verhindert, dass die
therapeutischen Dosen fu¨r eine verbesserte Tumorkontrolle erho¨ht werden ko¨nnen.
Deshalb sind Techniken gefordert, die die Bewegung des Tumors kontrollieren, um
den Anteil gesunden Gewebes, der bewegungsbedingt mitbestrahlt wird, zu min-
imieren.
Im Rahmen dieser Doktorarbeit wurden zwei Techniken entwickelt, die die intrafrak-
tionelle Bewegung reduzieren ko¨nnen und es damit erlauben, beweglichen Tumore
mit ho¨heren Einzeldosen zu bestrahlen. Zum Einen wurde eine neuartige Tech-
nik zur Verku¨rzung der Behandlungszeit und somit auch der intra-fraktionellen
Bewegung eingefu¨hrt und zum Anderen eine Methode entwickelt die es erlaubt
Atembewegungen auszugleichen. Zuna¨chst wurden zwei ausgleichsfilterfreie (FFF)
Strahlmodalita¨ten mit nomineller Energie 6 MV (X6FFF) und 10 MV (X10FFF)
kommissioniert. Diese Strahlmodalita¨ten erreichen Dosisleistungen von bis zu 24
Gy/min. Das fu¨hrt zu ku¨rzeren Bestrahlungszeiten und eventuell zu weniger intra-
fraktioneller Bewegung. Vor der Kommissionierung dieser Strahlmodalita¨ten, ist es
wichtig, das Verhalten der Messkammern in diesen neu-artigen Strahlmodalita¨ten
zu kennen. Deshalb wurde eine Studie durchgefu¨hrt, welche sieben verschiedene
Ionisationskammern untersucht. Alle belu¨fteten Ionisationskammern zeigten in den
Strahlmodalita¨ten mit Ausgleichsfilter eine Ionensammeleffizienz von u¨ber 0.995. In
den FFF Strahlen reduzierte sich die Ionensammeleffizienz um ungefa¨hr 0.005-0.009
(10 MV Strahl). Anders verha¨lt es sich mit der flu¨ssigkeitsgefu¨llten Ionisation-
skammer. Die Ionensammelausbeute fu¨r die Strahlmodalita¨ten mit Ausgleichsfilter
betru¨gt mehr als 0.99, fu¨r die FFF Strahlmodalita¨ten betra¨gt die Ausbeute nur 0.94
(10 MV mit einer Dosisleistung von 31.9 Gy/min). Zusammenfassend kann man
sagen, dass die luftgefu¨llten Ionisationskammern in den FFF Strahlmodalita¨ten fu¨r
Relativdosimeterie benutzt werden ko¨nnen, die flu¨ssigkeitsgefu¨llten Ionisationskam-
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mer jedoch nicht geeignet sind.
Im na¨chsten Schritt wurde eine Planungsstudie durchgefu¨hrt, die die FFF Strahlen
fu¨r die hypofraktionierte Bestrahlung von Prostata Tumore evaluiert. FFF Strahlen
unterscheiden sich im Profil von Strahlen mit Ausgleichsfilter, sie haben eine erho¨hte
Oberfla¨chendosis und einen niedrigeren Strahlqualita¨tsfaktor. Das Ziel der Pla-
nungsstudie war es herauszufinden, ob die FFF Strahlen fu¨r die Bestrahlung von
Patienten benutzt werden ko¨nnen und ob das Planungssystem die Pla¨ne mit diesen
Strahlmodalita¨ten optimieren kann. Die Bestrahlungsplanung wurde fu¨r sieben Pa-
tienten mit volumenmodulierter Bogenbestrahlungs Technik (VMAT) und vier ver-
schiedenen Strahlmodalita¨ten (X6 , X6FFF, X10, X10FFF) am TrueBeam Beschle-
uniger durchgefu¨hrt. Es gab keine signifikanten Unterschiede in der Zielvolumenab-
deckung (PTV Abdeckung) und bezu¨glich der Konformita¨t und der Homogenita¨t
zwischen den vier Modalita¨ten. Die mittlere Ko¨rperdosis wurde mit zunehmender
mittlerer Energie kleiner (R2 = 0.8275, p < 0.01). Die X10 Strahlmodalita¨t erho¨hte
die mittlere Dosis im Rektum signifikant um 2.6% (p < 0.01) im Vergleich zur X6
Modalita¨t. Die mittlere Dosis in der Blase erho¨hte sich um 1.3%, wenn der X6FFF
Strahl benutzt wurde und nahm um 2.3% ab, wenn mit X10FFF geplant wurde.
Zusammenfassend kann man sagen, dass der X10FFF Strahl den besten Kompromiss
bildet zwischen einer niedrigen Ganzko¨rperdosis und der Schonung der Risikoorgane
(Blase, Rektum). Patienten, die nur mit einem Bogen und dem X10FFF Strahl
bestrahlt wurden, hatten eine um 35% (2SD = 10%) verku¨rzte Bestrahlungszeit (3
Gy pro Fraktion) im Vergleich zur Bestrahlung mit den Strahlmodalita¨ten mit Aus-
gleichsfiter.
Nachdem mit der Planungsstudie gezeigt werden konnte, dass die FFF Strahlen
zur Planung von hypofraktionierten Schemata geeignet sind, wurde getestet, ob der
Beschleuniger die FFF Strahlmodalita¨ten dosimetrisch genau applizieren kann. Im
Vorfeld hierzu gab es mehrere Publikationen, die sich bezu¨glich der Genauigkeit
herko¨mmlicher Monitorkammern in FFF Strahlen kritisch gea¨ussert hatten. Das
Kontrollsystem der Monitorkammer muss aufgrund des erho¨hten Dosisoutputs im
FFF Modus schneller reagieren ko¨nnen. Um die dosimetrische Genauigkeit zu
verifizieren, wurde die patientenspezifische Qualita¨tssicherung von 4 Radiothera-
piezentren analysiert. Sowohl die VMAT als auch die intensita¨tsmodulierte Technik
(IMRT) wurden untersucht. Die Pla¨ne wurden anhand des Gamma U¨bereinstim-
mungs Indexes (GAI) beurteilt, der eine Dosisdifferenz von maximal 3% und eine
ra¨umlich Diskrepanz von maximal 3 mm tolerierte. Die Patienten spezifische QA von
224 Patienten mit 1-6 Zielvolumina an verschiedenen anatomischen Orten und mit
Fraktionsdosen von 1.8 Gy - 25 Gy wurde ausgewertet: 88 dieser Patienten wurden
mit der X6FFF Strahlqualita¨t bestrahlt und 136 mit der X10FFF Strahlqualita¨t.
Verifiziert wurden die Dosisverteilungen mit gafchromischen Filmen im wassera¨quiv-
alenten Plattenphantom oder mit Ionisationskammern, oder mit dem DELTA4, oder
dem ARCCHECK oder dem MATRIXX Phantom. Es hat sich gezeigt dass es zwis-
chen IMRT und VMAT Bestrahlung in Bezug auf die Genauigkeit der Dosisberech-
nung und der Dosisapplikation am Beschleuniger keinen signifikanten Unterschied
xgab (IMRT: GAI = 99.3% (1SD = 1.1%); VMAT: GAI=98.8% (1SD = 1.1%)).
Ebenso gab es keinen signifikanten Unterschied in der Genauigkeit zwischen den
zwei Strahlmodalita¨ten (X6FFF: GAI = 99.1% (1SD = 1.0%); X10FFF: GAI=98.8%
(1SD = 1.2%)). Zusammenfassend haben unsere Ergebnisse gezeigt, dass die FFF
Strahlmodalita¨ten des TrueBeam Beschleunigers in Verbindung mit dem Eclipse
Planungssystems sicher und dosimetrisch genau sind.
FFF Strahlmodalita¨ten werden aufgrund ihrer hohen Dosisleistung vorallem fu¨r
hypo-fraktionierte Bestrahlungen verwendet. Im Rahmen dieser Doktorarbeit wurde
die klinische Awendung der FFF Strahlen fu¨r extra-kranielle La¨sionen ausgewertet,
insbesondere sollte die erho¨hte Stabilita¨t aufgrund der ku¨rzeren Behandlungszeiten
belegt werden. Sechzehn Patienten mit Lungenkarzinomen und 10 Patienten mit
Tumoren im Abdomen wurden mit dem internen Zielvolumen Konzept (ITV) be-
strahlt. Die Sicherheitssa¨ume zwischen dem ITV und dem PTV wurden mit Hilfe
der Van Herk Formel berechnet. Zusa¨tzlich wurde untersucht, wie stabil der Tumor,
wa¨hrend der aufgrund der FFF Strahlen kurzen Behandlungzeit ist. Die mittlere
Strahlzeit war 1.6 min (1SD = 0.6 min) und die mittlere Gesamtzeit einer Behand-
lungssitzung 18.5 min (1SD = 3.5 min). Der Zeitvorteil fu¨r die FFF Strahlen im
Vergleich zu denen ohne Ausgleichsfilter war fu¨r hohe Fraktionsdosen (>4 Gy) statis-
tisch signifikant. Der Zeitgewinn wurde mit zunehmender Fraktionsdosis gro¨sser. Im
Mittel bewegte sich der Tumor wa¨hrend der Bestrahlung um 2mm, daraus wurde ein
Sicherheitssaum von 6 mm berechnet. Die Verwendung von FFF Strahlmodalita¨ten
fu¨hrt zu einer zeiteffizienten Durchfu¨hrung von SBRT Behandlungen und einer sta-
bilen Tumorposition. Weitere Studien sind no¨tig um die Wirkung der FFF Strahlen
sowie die Nebenwirkungen zu quantifizieren.
Durch die Anwendung von Ausgleichsfilter-freien Strahlen kann die intra-fraktionelle
Bewegung des Patienten sowie die Bewegung der Prostata reduziert werden. Fu¨r
periodische Atembewegungen kann jedoch durch die Anwendung der FFF Strahlen
keine Reduktion erwartet werden.
Im letzten Teil dieser Arbeit wurde ein Tracking System entwickelt und evaluiert, das
es ermo¨glicht Atembewegungen mit dem Behandlungstisch auszugleichen. Drei ver-
schiedene Sensoren zur Detektion der Bewegung wurden getestet: Das topometrische
System Topos (Cyber Technology), das Respiratory Patient Monitoring System
(RPM) (Varian Medical Systems) und ein Laser Triangulations System (Micro Ep-
silon). Ein Proportional-Integral Kontrollsystem wurde implementiert, um der Atem-
bewegung gegenzusteuern. Die geometrische Unsicherheit des Systems wurde quan-
tifiziert indem die mittlere absolute Abweichung zur Null-Bewegungslinie mit und
ohne Tracking verglichen wurde. Ein hexapod system (Physics Instruments, Ger-
many) hat sieben physiologische Atembewegungskurven und zwei sin6 Funktionen
(0.33 Hz und 0.17 Hz) nachgefahren. Diese Bewegung wurde mit dem Behand-
lungstisch Protura (Civco Medical Systems) ausgeglichen. Es hat sich gezeigt, dass
kurze Totzeiten no¨tig sind, um allen Atemfrequenzen folgen zu ko¨nnen. Mit dem
Lasersystem, welches die ku¨rzeste Todzeit hatte, konnten alle Atemkurven aus-
geglichen werden. Ein Anstieg von 60 ms (Laser System) auf 130 ms (RPM System)
xi
fu¨hrte dazu, dass die sin6 Funktion (0.33 Hz) nicht mehr ausgeglichen werden konnte.
Das TOPOS System mit der gro¨ssten Totzeit von 300 ms konnte nur vier Atembe-
wegungsmuster ausgleichen. Mehr wissenschaftliche Arbeiten sind no¨tig, um diesen
Prototypen so zu erweitern, dass er auch interne Bewegungen ausgleichen kann.
Durch die Entwicklung des Tracking Systems wurde ein zweiter Ansatz zur Reduk-
tion von intra-fraktioneller Bewegung aufgezeigt und evaluiert. Das Ziel fu¨r die
Zukunft ist, die FFF Strahlen mit der aktiven Kompensation der intra-fraktionellen
Bewegung zu kombinieren, um eine optimale Bestrahlung zu erzielen.

Chapter 1
Motivation and Outline of the
thesis
1.1 Motivation
Currently, standard external beam radiotherapy consists of 50 to 78 Gy of radiation
separated into 1.8 to 2 Gy fractions given daily for 7 to 9 weeks. The clinical ex-
perience on these fractionation schedules is large and the normal tissue tolerances
are well known [8]. Studies of the response of cancer cell cultures to radiation, how-
ever, suggest that fractions with a dose larger than 2 Gy may be more effective.
Hypofractionated treatment schedules are proposed for several types of cancers, in-
cluding breast cancer [13, 7, 132], prostate cancer [37, 82, 73], lung cancer [59, 90]
and liver cancer [62, 75]. However, concerns about normal tissue toxicity require
a more effective normal tissue sparing than for conventional fractionations. A re-
duction of safety margins between the actual gross tumor volume (GTV) and the
treated volume (PTV) is needed to better spare organs at risk. For tumors of the
lung, liver, breast and prostate a large part of the safety margin is to account for
motion of the tumor during the treatment session [115, 116]. Two approaches to
reduce intrafractional motion of moving tumors, to be able to increase the dose
per fraction, are implemented and evaluated within the frame of this thesis. First,
flattening filter free beams were implemented for clinical use. Flattening filter free
beams have an increased dose rate compared to conventional beams, which leads to
reduced treatment times and potentially to reduced intrafractional motion. At the
University Hospital we were the first clinic in the world to have these flattening filter
free beams available for clinical use. Within the frame of this thesis the FFF beams
were characterized, suitable tools for beam characterisation were found and patient
specific quality assurance was addressed. Additionally the dosimetric and time ben-
efit for hypofractionated treatments of lung and prostate tumors were evaluated.
The use of flattening filter free beams can reduce motion of the patient as well as
prostate motion due to the shorter treatment times, however for periodic respiratory
motion there is no benefit expected. In the second part of the thesis the reduction
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of safety margins for respiratory motion was addressed. A couch tracking approach
to compensate respiratory motion was implemented and evaluated. Not addressed
within this thesis are further methods for treatment margin reduction such as im-
age guided radiotherapy, positioning devices for patients, gated treatments and four
dimensional planning.
1.2 Outline and Contribution to the Chapters
In Chapter 2 the fundamentals of the research performed within the frame of this
thesis are explained. The basic function of a linear accelerator, the accuracy of
linear accelerators and the properties of flattening filter free beams are described
in Chapter 2.2-2.4. Additionally motion management techniques, hypofractionation
and margin concepts are discussed (Chapter 2.5-2.7). The Chapter was written by
myself, part of it will be published in a review article in the SPG Mitteilungen.
Within the frame of this thesis two flattening filter free (FFF) beams with nominal
energy 6 MV (X6FFF) and 10 MV (X10FFF) were commissioned. As described in
Chapter 2.4, these beams allow a maximum dose rate of up to 24 Gy per minute
((X10FFF in depth of maximum dose, a source-surface distance of 100 cm and a
field size of 10x10 cm2), leading to shortened treatment times and eventually less
target movement during a treatment session. A prerequisite for commissioning is
the knowledge of the behaviour of detectors in the high dose per pulse FFF beams.
In Chapter 3 a study, which evaluates seven widely used ionization chambers, is
described. The study was designed by myself and all the measurements were per-
formed with the support of Jan Hrbacek. Additionally the manuscript was drafted
by myself.
FFF beams have a higher dose rate on the central axis than flattened beams, an
increased surface dose and a reduced beam quality factor. To show that the FFF
beams can be used for treatment planning, a planning study for hypo-fractionated
prostate treatments was performed in Chapter 4. In this planning study the use
of FFF beams for patient treatments and the capability of the planning system
to optimize the FFF beams were evaluated. Dose distributions, out-of field doses
and treatment times were evaluated and compared to conventional flattened beams.
Daniel Zwahlen and myself are equally contributing authors to this manuscript.
The execution of the treatment planning study and the corresponding statistical
analysis were performed by myself. Together with Daniel Zwahlen the results were
interpreted. Daniel Zwahlen put the results into a clinical context and drafted intro-
duction and conclusion. Materials and methods and results were drafted by myself.
After the verification of the planning system, the capability of the linear accelerator
to deliver the high dose rate beams was investigated and is described in Chapter 5.
The study was motivated by early concerns regarding the safe delivery of FFF beams
[39], especially regarding the monitor chamber, which is used to steer the beam. The
monitor chamber is described more in detail in Chapter 2.2. Pre-treatment quality
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assurance (QA) data from 4 clinics were analysed with different verification devices
to assess reliability and dosimetric accuracy of FFF beam delivery for intensity
modulated radiotherapy (IMRT) and volumetric modulated radiotherapy (VMAT)
techniques. The multi-center study was initiated by myself, the data was collected
and the manuscript drafted by myself.
FFF beams are, due to the high available dose rate, often considered for hypo-
fractionated treatments of breast, lung and prostate cancer. In Chapter 6 the clin-
ical application of FFF beams for extra-cranial lesions is discussed. The internal
target volume (ITV) concept as described in Chapter 2.7.1 was used to treat 16
patients with lung tumors and 10 patients with abdominal tumors. ITV to planning
target volume (PTV) margins were calculated according to the Van Herk Formula
(Chapter 2.6) and tumor stability was determined for the short treatment times of
FFF beams. The clinical study was designed by Oliver Riesterer and myself. The
data evaluation and parts of the treatment planning were done by myself.
As a last part of the thesis the possibility of couch tracking (Chapter 2.7.3) to com-
pensate for respiratory tumor motion was evaluated (Chapter 7). Since this is a
technique which is not yet clinically used and there are no commercial solutions
available, the control system of the couch was implemented. Three different motion
detection sensors with different lag times were evaluated: the topometrical system
Topos, the respiratorygating system (RPM) or the laser triangulation system (Mi-
cro Epsilon). In a pre-clinical study the compensation of the patient breathing was
geometrically and dosimetrically analysed. My contribution to this project was the
development of the first prototype systems, which was further improved in close
collaboration with the control system group of the ETH Zu¨rich. The system was
evaluated by myself and the manuschrift was drafted by myself.
In the last Chapter a conclusion on the work done in this thesis is given and an
outlook on further possible investigations and applications of the research described
in Chapter 3 to 7 is drawn.
Chapter 2
Introduction ∗
2.1 Radiation Therapy
Cancer is the second most common cause of death in Switzerland (Todesursachen-
statistik, BFS, [10]). In 2011, 9054 men and 7223 women died of cancer. For men
the leading cause of cancer death is lung cancer, followed by prostate cancer. For
women the leading cause of cancer death is breast cancer, followed by lung cancer
[131].
Different treatment approaches, such as surgery, radiation therapy and chemother-
apy are used to treat cancer. Todays cancer patient typically receives a multimodal
treatment that include at least two, or all three treatment modalities. Depending on
the tumor location, cell type tumor grade and the general condition of the patient,
the clinician decides together with the patient on an adequate treatment option.
During the course of their disease 50-60% of all cancer patients will be treated with
radiotherapy at least once, which underlines the importance of the discipline. [101].
In radiation therapy ionising radiation is used to kill or control malignant cancer
cells. High energy photons and electrons are most frequently used. Recently, some
cancer treatment centers have been built, that treat with protons, neutrons and
heavy ions.
The physical effects of high energy photons as well as charged particles in mat-
ter (e.g. human tissue) are indirect and direct ionizations of atoms. Photons are
mainly indirectly ionizing. They produce high energy electrons, once they interact
with matter. The three main interaction processes of photons in matter are: Pho-
toelectric effect, Compton Effect and Pair Production. In the megavoltage (1-20
MeV) range, the most commonly photon energy range used in radiation-oncology
the Compton Effect is predominant. The high energy electrons have enough energy
to produce a large number of ionizations by collisions. Charged particles are directly
ionizing. They have enough energy to produce ionizations by collisions as they pen-
etrate into matter. The major biological effect of ionizing radiation is DNA damage,
∗Parts of this chapter will be published in SPS Mitteilungen, No 40, Nov 2013 [71].
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e.g. when a secondary electron or a charged particle ionizes DNA molecules directly
or indirectly by hydroxyl radicals that interact with the DNA. Hydroxyl radicals
are produced as a result of the ionization and chemical reaction of water molecules.
By radiating a tumor to 1-2 Gy to a tumor more than 1000 single strand breaks
and approximatly 40 double strand breaks of the DNA double helix are induced
per cancer cell. This damage could theoretically be repaired by the cellular DNA
damage repair system. Cancer cells however, are much more sensitive to radiation
than normal cells. Cancer cells divide more often and are therefore more vulnerable
to radiation and they often have defective repair systems due to DNA mutations.
Two principle techniques exist in radiation therapy, brachytherapy and external
beam radiotherapy. In brachytherapy, the radiation source is placed inside the body
of the patient in close proximity to the tumor, or even within the tumor. In external
beam radiotherapy (EBRT) the radiation targets on a specific part of the body from
outside. The dose in EBRT can be delivered to the target using different techniques.
Three dimensional conformal radiotherapy (3DCT) uses static multi leaf collimators
(MLC) at different gantry and collimator angles to block critical organs. More re-
cently, dynamic MLC techniques were introduced into clinical practise. Modulated
techniques such as IMRT and VMAT modulate the energy fluence using the MLC,
the dose rate and or the gantry speed.
2.2 Linear accelerators in Radiation Therapy
High energy photons or electrons (4-20 MeV) produced by a linear accelerator are
most commonly used in radiation therapy to treat tumors. A typical linear acceler-
ator consists of 5 main parts [63]:
 The modulator; serving as a power supply for the linear accelerator.
 The stand; the non-rotating part, that contains the water supply and the high
frequency amplifier (klystron or magnetron).
 The gantry; the rotating part of the linear accelerator. All beam generating
and shaping parts are located in the gantry.
 The imaging system: Planar megavoltage (MV) or kilovoltage (kV) imaging
is available on all commonly used linear accelerators to compare the internal
anatomy of the patient to the anatomy at the planning computer tomography
(CT). More advanced imaging such as kV or MV cone beam CT (CBCT) is
used for more accurate tumor targeting.
 The treatment couch; used for positioning of the patient. Most commonly
four dimensional corrections (longitudinal, lateral, vertical and rotation) are
applied, however, six degree of freedom (additionally pitch and roll) couches
were recently introduced in radiation therapy. There is a potential to use the
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treatment couch for dynamic couch tracking, which is discussed in more detail
in Chapter 7.
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Figure 2.1: Shematic drawing of a linear accelerator
Figure 2.1 is a schematic drawing of a high energy linear accelerator, as the one
installed at the University Hospital in Zu¨rich. The first part of the beam generation
is the electron gun, which consists of an anode and a cathode. The cathode is
heated and a negative potential is applied to it. This causes the electrons to exit the
anode material (glow emission). They are focused and accelerated by the anode and
injected into the accelerator tube. In the tube a high frequency wave (3 GHz) further
accelerates the electrons to a maximum energy between 4 MeV and 20 MeV. The
energy switch determines the length of the accelerating wave within the accelerator
tube. The longer the wave the higher the residual energy of the electrons. The
klystron inside the stand produces the high frequency wave. The modulator supplies
the power for the klystron and the electron gun.
After leaving the waveguide, the electrons are bent by 270° by a magnet. If electrons
are used for treatment, the electron pencil beam is scattered multiple times on
scatteing foils, to broaden the beam. The dose, as well as the symmetry and the
flatness of the beam are checked in two monitor chambers. The beam is collimated
by a tubus and, depending on the size and shape of the tumor an adequate insert
defines the shape of the beam before irradiating the patient.
If photons are used for treatment, a tungsten target is placed in the electron beam’s
path to produce high intensity Bremsstrahlung. The primary collimator selects
the middle part of the beam by cutting off the beam’s field edges. Due to the
higher probability of forward scattering, there is more dose in the center part of the
beam than on the sides. This can be corrected for by using a flattening filter. The
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flattening filter is a metal cone that absorbs dose more in the center part of the beam
than on the sides to flatten the dose profile. The flatness, as well as the symmetry
and the output of the beam are checked by the two monitor chambers. For photon
beams, several beam shaping devices are available. The collimator jaws have a very
low transmission of 0.1% and used for the basic collimation of the beam. The MLCs
are used to achieve more complex shapes. However, the transmission through the
MLCs and therefore the dose outside the field is higher (1.2%, [53]) than that of
the jaws. Additionally wedges or blocks can be used to further modify the beam to
optimized dose to the target [63].
2.3 Accuracy of linear accelerators
The dosimteric as well as geometric accuracy of linear accelerators is essential for
the treatment outcome. Modern linear accelerator can achieve sub-millimeter ac-
curacy in all axes as Depuydt et al [25] discussed in their study for various linear
accelerators. They have performed starshots of the rotational axes of the gantry,
the couch and the collimator of a Varian TrueBeam linear accelerator, a Brainlab
Vero system, an Accuray Tomotherapy system, as well as an Elekta Synergy linear
accelerator. Figure 2.2 shows the setup used to perform the gantry starshot as well
as the digitized image of the film. Similarly, Kim et al [64] published an accuracy of
Figure 2.2: Left: Setup used to perform the gantry starshot; Right: digitized image
of the film. The film is irradiated from various angles with a a field size of 20 x 0.5
cm2. The Intersection of the lines defines the position and the size of the isocenter
circle
below 1 mm of the rotational axes of the Novalis Tx linear accelerator. Their study
was performed using a test similar to the classical Winston Lutz test [81].
Beside the geometric accuracy the dosimteric accuracy of the is important for the
treatment outcome. Dutreix [29] concluded that an overall precision of +/-5% on
the absorbed dose, at any point in the patient, is required to achieve the predicted
treatment outcome. According to the ICRU report 24, the available evidence for
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certain types of tumors, points to the need for a dosimetric accuracy of +/-5% at
95% confidence level in the delivery of an absorbed dose to a target volume [54].
Fogliata et al [35] recently showed an agreement of 3% (gamma agreement score
100% for 3%/3mm) between measured and calculated dose distributions in water,
bone and normal lung tissue, if an advanced type B dose calculation algorithm is
used. Type B algorithm take the scatter in different materials better into account
compared to traditional type A algorithms. Similar Aarup et al [1] showed for lung
tissue an accuracy within 3% for the Analytical Anisotropic Algorithm and the Col-
lapsed Cone Convolution algorithms (both type B algorithms).
To investigate the overall accuracy of the treatment process end to end testing is
being conducted [130]. The phantom undergoes the whole treatment chain as a
patient would do, a magnetic resonance image (MRI) and a CT are performed on
the phantom. The two imaging modalities are then fused. The organs at risk as
well as the tumor gross target volume (GTV) are contoured on the MRI, whereas
the treatment plan is created and the dose distribution is calculated on the CT.
The treatment plan is irradiated on the phantom at the treatment machine. High
resolution detector systems (radiosensitve film or gel) record the dose distribution,
which is evaluated afterwards. An overall accuracy of 3%/2mm can be achieved on a
static phantom [130]. However patient motion and change in anatomy of the patient
can lead to additional inaccuracy. Within the frame of this thesis different investi-
gations were done to reduce patient motion using a faster treatment technique with
FFF beams (Chapter 4 and 6) and a couch tracking motion compensation method
(Chapter 7). The goal was to reduce the geometrical inaccuracy of the treatment to
be similar to the inaccuracy of the linear accelerator.
2.4 Flattening filter free beams
Historically, a relatively flat beam profile over the entire treatment field was de-
sired to calculate dose distributions in a simplified way. This was achieved using
the flattening filter. With beam intensity modulated techniques, including IMRT
and VMAT, the MLC is used to modify the fluence distribution producing optimal
fluence maps for FFF beams similar to those with flattening filter [123, 124]. An
increasing interest in FFF technology results from the expectation that it will allow
faster treatment delivery with dose rates up to 24 Gy/min [38] (X10FFF in depth of
maximum dose, a source-surface distance of 100 cm and a field size of 10x10 cm2).
The high dose rate can be achieved with FFF beams, because the photons are not
absorbed in the flattening filter as for conventional beams. It was shown by several
investigators that treatment efficiency is increased by a factor of 2-4 for stereotactic
body radiotherapy (SBRT) [111, 95].
The beam generation for the FFF beams is similar to the generation for flattened
beams. The initial electron pulse, the accelerating wave as well as the magnetic
strength of the the bending magnet and most of the time the target are the same
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(figure 2.3) as for flattened beams. For higher energies a thicker target can be used,
w ith fla tten ing filte r fla tten ing filte r free
target: pho ton rad ia tion ge ts produced (no  
d iffe rence be tw een FFF  and  fla ttened beam s)
flattening filter: fla ttens the
beam and absorbs b ig part o f 
the rad ia tion (fla tten ing filte r
is m ade of m eta l)
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patient plane / treatment plane
Figure 2.3: The only difference in beam generation between flattened and FFF is
the missing flattening filter for FFF beams
to reduce contaminating electrons. The missing flattening filter leads to the dif-
ferences in beam characteristics. The most obvious difference is the beam profile
(figure 2.4). The FFF profile has a higer dose rate on the central axes compared to
the field edges. Hrbacek et al [53] showed that the energy fluence ratio can be up to
a factor of four for a beam with nominal energy of 10 MeV.
Flattened photon beams are partially absorbed in the flattening filter. Mainly the
low energy part of the spectrum is absorbed, which leads to beam hardening. FFF
beams don’t experience beam hardening and therefore have a lower mean energy
compared to flattened beams (figure 2.4). Additionally the flattening filter is the
main source of photon scatter in the beam path. This leads to higher out of field
dose for conventional beams compared to FFF beams. Another effect, which leads
to a reduced out of field dose, is less transmission through the head shielding as the
beam production efficiency is higher. Several investigations showed the reduction
of out of field dose in a water phantom as well as in an anthropomorphic phantom
[53, 66, 20].
2.5 Hypofractionation
The optimal fractionation scheme strongly depends on the type of tumor. A certain
amount of radiation causes non-repairable and repairable damage to tissue depend-
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Figure 2.4: Top: Depth dose curve of a X10FFF beam compared to a flattened beam.
The FFF beam has a lower mean energy (measured at a source surface distance of 90
cm). Bottom: Profile of a X10FFF beam compared to a flattened beam (measured
at a source surface distance of 90 cm and a depth of 10 cm).
ing on the tissue type. Many fractions with a lower dose per fraction most effectively
balance tumor control and damage to healthy tissue, if the ratio of non-repairable
to repairable damage (therapeutic ratio) for the tumour is greater than the ratio
for the surrounding healthy tissue. If these ratios are comparable or the ratio for
the surrounding tissue is larger, then a larger dose per fraction (hypofractionation)
with a lower total dose is most effective. The clinical experience on the use of con-
ventional fractionation schedules of 2 Gy per fraction is large and normal tissue
tolerances are well known. Studies of the response of cancer cell cultures to radi-
ation, however, suggest that fractions with a dose larger than 2 Gy may be more
effective. Hypofractionated treatment schedules are proposed for several types of
cancers, including breast cancer [13, 7, 132], prostate cancer [37, 82, 73], lung cancer
[59, 90] and liver cancer [62, 75]. Concerns about normal tissue toxicity require a
more effective normal tissue sparing than for conventional fractionations. Multiple
advancements have been made in the past ten years to achieve less dose deposition to
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the surrounding tissue. Image guided radiotherapy (IGRT) using MV portal images,
kV- image pairs and kV CBCTs have led to better localisation and therefore allow
a reduction of treatment margins [44, 100]. Advanced treatment techniques such as
IMRT sliding window, VMAT and tomotherapy result in an improved conformity
of dose distributions with the option of simultaneous integrated volumes of higher
doses [68, 96, 31]. However hypofractionation, reduced margins and micro structure
adapted dose distributions with sharp gradients require a stable tumour position.
Comparing pre and post treatment CBCT, Reggiori et al showed that the mean
movement of the prostate is 0.16 cm (+/- 0.06) during a time period of 4-5 min
and increases to 0.29 cm (+/- 0.16) during a time interval of 8 min [107]. Therefore
tumor motion management is needed cope with intra-fractional motion.
2.6 Margins in Radiation Therapy
One of the first steps in treatment planning in radiation therapy is the definition of
the target volume. According to the ICRU guidelines 50 and 62 [55], different target
volumes are defined. The gross tumor volume (GTV) is the gross demonstrable
extent and location of the tumor [56]. It includes the primary tumor, metastatic
regional node(s) and or distant metastasis. The clinical target volume (CTV) is
defined as the GTV and or subclinical malignant disease with a certain probability
of occurrence considered relevant for therapy [56]. The planning target volume
(PTV) was first introduced in ICRU report 50 [55]. The dose in radiation therapy
is prescribed to the PTV. The PTV extends the CTV by the uncertainty of the
dose delivery (figure 2.5). This ensures the coverage of the CTV by the prescribed
dose. Geometrical uncertainties in RT include both treatment preparation variations
(systematic errors such as equipment tolerances, planning setup error, organ motion
and target volume delineation) and execution variations (random errors such as
treatment setup error, inter- and intra-fraction organ motion). The different types
of errors need to be added or combined. If the errors are added linearly, the resulting
PTV is often too large. This leads to unnecessary irradiation of healthy tissue and
might increase the probability of unwanted side effects. A more advanced approach
for margin calculation based on the probability distribution was introduced van Herk
et al [122]. The margin M ensures that the minimum dose to the CTV is 95% of the
prescribed dose for 90% of the patients:
M = 2.5Σ + 1.64(σ − σP ) (2.1)
σP describes width of beam penumbra fitted to a Gauss function, Σ represents the
systematic and σ the random error [122, 108]. Systematic errors can be calculated
for intra-fractional motion, contouring as well as setup; Random errors for intra-
fractional motion and patient setup. The total systematic error Σ is then calculated
as:
Σ = (Σ2contour + Σ
2
setup + Σ
2
IFM)
1/2 (2.2)
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Figure 2.5: The GTV is the tumor volume defined by imaging, the CTV extends
the GTV by the subclinical malignant disease and the PTV extends the CTV to
account for uncertainties in dose delivery.
The total random error σ is calculated as:
σ = (σ2setup + σ
2
IFM)
1/2 (2.3)
2.6.1 Internal target volume
In the ICRU report 62 [56] it is recommended to add an internal margin (IM) around
the CTV to compensate for physiological tumor motion and deformation. The ITV
includes the CTV and the IM (figure 2.6). ITVs are commonly used for tumors that
move due to breathing. The difference between GTV and ITV can be quite large.
In the case of figure 2.6 the GTV is 1.76 ccm, whereas the ITV is 9.82 ccm.
Figure 2.6: The ITV is outlined in red in three breathing phases (inhale, exhale and
mid phase. The tumor remains inside the ITV for all three phases
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2.7 Motion management
As shown in Chapter 2.3 modern accelerators achieve sub-millimeter accuracy. How-
ever not all tumors are stable during the treatment session. Tumors in the lung can
move up to 16 mm [114], in the liver up to 34 mm [110] and the thoracic wall moves
up to 14 mm [105] due to respiratory motion. Prostate tumors move up to 9 mm
mainly due to bowel motion and bladder filling [88]. Tumor motion management is
needed to irradiate the tumor while sparing the healthy tissue. This becomes more
important for hypo-fractionation, where high doses are applied in a small number of
treatment fractions. Several methods for tumor motion management are described
below.
2.7.1 ITV concept
As described in section 1.4.1, the ITV accounts for changes in position of the GTV as
well as deformation of the GTV due to organ motion. The ITV concept is commonly
used for lung and liver tumors [58, 138]. The amount of motion is determined using
a four dimensional CT (4DCT). During a 4DCT many CT datasets are acquired,
each of them corresponds to a particular respiration phase. In each respiration phase
the GTV is contoured and the ITV is defined as the sum of all phases (figure 2.6).
This ensures sufficient target coverage however leads to unnecessary dose to healthy
tissue. Additionally for modulated techniques such as IMRT and VMAT, there is
evidence of an interplay effect between the moving tumor and the moving MLC,
which leads to under- and overdosage of the PTV [127, 112].
2.7.2 Gating
The goal of gated treatement delivery is to ensure accurate targeting of the moving
tumor, while sparing the healthy tissue. The breathing motion of the patient is mon-
itored and the beam is triggered by this signal. Only during a certain phase range
(phase gating) or a certain amplitude range (amplitude gating) the beam is switched
on. The higher the desired accuracy is, the tighter becomes the window between
upper and lower limit. This results in shorter duty cycles and longer treatment
times. Figure 2.7 shows an example of amplitude based gating. The planning CT is
recorded in the same phase or amplitude range. Additional to free breathing gating,
a triggered radiation can be realized during patient’s breath-hold. For breath-hold
gating the patient is encouraged to hold his breath for as long as possible.
Several methods exist to track the breathing signal of the patient. Most of them
rely on optical detection methods of the surface of the patient or at least of a point
on the surface of the patient. The respiratory position monitoring (RPM) gating
system (Varian Medical System) uses an infrared camera, which detects the reflected
light from a marker block that is placed on the chest wall of the patient. Several
investigations have described the application of the RPM system for breast, lung
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Figure 2.7: Amplitude based gating. The beam is switched on, if the respiration
(green line) is within a certain amplitude range (in this case between the orange and
blue line).
and liver treatments [128, 57, 43]. Surface detection systems [76, 9] have the advan-
tage that gating can be performed at more than one point. A certain area of the
body surface can be selected for gating. This might improve the correlation between
external surface motion and internal tumor motion. Wong et al [137] published the
idea to use a spirometer for gating. Gating based on spirometry as well as surface
detection relies on a stable correlation model between the internal tumor motion
and the external motion or air flow. Several publications have shown that this is
not necessarly true and the correlation from the planning CT might not be valid on
the treatment machine for some patients [41, 50].
Butler et al [16] conducted a study to compare the dose to the healthy lung with and
without gated irradiation of lung tumors. They analysed the masses of lung tissue
receiving at least 20 Gy (M20). A clear benefit of gated treatments (reduction of
M20 between 3% and 57%) over non-gated treatments was found. The main disad-
vantage of gated treatment delivery is the extended treatment time. Depending on
the duty cycle (time in which the beam is switched on), the treatment time can be
prolonged up to a factor of four (compare figure 2.7)
2.7.3 Tracking
Tumor tracking is another way to cope with intra-fractional motion. It can be re-
alized by dynamically following the target volume with the radiation beam. This
was first implemented in a robotic radiosurgery system, the CyberKnife system [2],
and has been further realized by the use of a dynamic MLC [89] and the gimbaled
head of the VERO system [25]. Another possibility is to leave the treatment beam
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undisturbed but to move the treatment couch in order to achieve a stable tumor
position. Several visibility studies have been performed showing the capability of
different couch systems to perform tracking. Already in 2005 D’Souza et al [27] pre-
sented a couch tracking system based on a hexapod, which could perform tracking
for slow breathing periods of 16s. More recently Buzurovic et al [18], Haas et al
[46] and Wilbert et al [135] have developed more advanced couch control systems
using proportional integral feedback systems. However, none of these couch tracking
systems is clinically available.
Menten et al [85] compared a dynamic couch tracking system with a MLC track-
ing approach for periodic organ motion as well as prostate motion. MLC tracking
reduced the respiratory induced motion to 2.0 mm (from 4.1 mm). The treatment
couch tracking reduced the amplitude to 2.1 mm. Although this suggests a higher
accuracy of the MLC tracking system, dosimetric evaluation of the system showed
that the gamma agreement index (GAI) scores between tracked and static dose dis-
tributions were higher for treatments performed with couch tracking. GAI scores
for tracking of prostate motion were 85% for MLC tracking and 95.3% for treatment
couch tracking.
Besides the active tracking component, such as the treatment couch or the MLC,
fast motion detection is essential for real-time tumor tracking. Several systems are
suggested in the literature, ranging from surface detections systems [76, 9], kV- or
MV- marker detection [78, 77] to the detection of three implanted resonant circuits
(beacons) in a magnet array [136, 5]. The advantage of a surface detection system
is that the patient does not receive any additional dose, however the correlation be-
tween the target volume and the surface of the patient might not be stable [41, 50].
MV and kV imaging as well as beacon detection has the advantage of imaging the
internal anatomy of the patient. However kV imaging adds a large additional dose
to a large volume of the patient. Beacon detection seems to be a good alternative
however it leads to some limitation in treatment planning because certain angles can
no longer be used for irradiation due to additional equipment requirements. Addi-
tionally the necessary extra equipment is expensive and not standardly supplied
with linear accelerators. Chapter 7 describes the development and evaluation of a
tracking system with clinical available equipment. Three different motion detection
sensors are evaluated within the tracking system.
Chapter 3
Ion recombination correction for
different ionization chambers in
high dose rate flattening filter free
photon beams ∗
3.1 Abstract
Recently there has been an increased interest in flattening filter free linear accel-
erators. Removal of the filter results in available dose rates up to 24 Gy/min (for
nominal energy 10 MV in depth of maximum dose, a source-surface distance of 100
cm and a field size of 10x10 cm2). To guarantee accurate relative and reference
dosimetry for the flattening filter free beams we investigated the charge collection
efficiency of multiple air-vented and one liquid ionization chamber for dose rates up
to 31.9 Gy/min. For flattened beams, the ion collection efficiency of all air-vented
ionization chambers (except for the pinpoint chamber) was above 0.995. By remov-
ing the flattening filter we found a reduction in collection efficiency of approximately
0.5-0.9 % for a 10 MV beam. For flattening filter free beams, the Markus chamber
showed the largest collection efficiency of 0.994. The observed collection efficiencies
were dependent on dose per pulse, but independent of pulse repetition frequency.
Using the liquid ionization chamber the ion collection efficiency for flattened beams
was above 0.990 for all dose rates. However, this chamber showed a low collection
efficiency of 0.940 for the flattening filter free 10 MV beam at a dose rate of 31.9
Gy/min. All investigated air-vented ionization chambers can be reliably used for
relative dosimetry of flattening filter free beams. The order of correction for ref-
erence dosimetry is given in the manuscript. Due to their increased saturation in
high dose rate flattening filter free beams, liquid ionization chambers appear to be
∗This chapter has been published in Physics in Medicine and Biology, Vol. 59, No. 9, April
2012 (Lang et al [69]).
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unsuitable for dosimetry within these contexts.
3.2 Introduction
Recently there has been an increased interest in flattening filter free (FFF) lin-
ear accelerators [125, 20, 65, 53]. Removal of the filter results in available dose
rates up to 14 Gy/min and 24 Gy/min for nominal energies of 6 and 10 MV (in
depth of maximum dose (dmax), a source-surface distance (SSD) of 100 cm and a
field size of 10x10 cm2), respectively. To guarantee accurate relative and reference
dosimetry for such flattening filter free beams we investigated the charge collection
efficiency of multiple air-vented and one liquid ionization chamber for dose rates up
to 31.9 Gy/min. The two main processes leading to ion recombination are ’initial
recombination’ and ’general recombination’. Initial recombination is caused by the
recombination of two particles originating from the same particle track. It has been
previously shown by several authors that within air-vented ionization chambers this
contribution is minimal and independent of dose rate [15, 26]. General recombi-
nation occurs when particles originating from different particle tracks recombine.
Boag [11] developed a theoretical method to account for the general recombination
in both pulsed and continuous beams. He proposed the two voltage method [12] to
determine the correction for incomplete collection of ions at sufficiently high applied
voltages. Since then, numerous investigations regarding the ion collection efficiency
of different chambers used for reference dosimetry under a range of conditions have
been published [15, 26, 48, 24, 14]. Recently, Bruggmoser et al [14] determined satu-
ration coefficients for a selection of plane parallel and cylindrical chambers in pulsed
photon and electron beams up to 42 mGy/pulse. For liquid ionization chambers the
two voltage method cannot be applied because the effect of initial recombination
cannot be neglected due to the high ionization density in the particle track and the
short mean free path of ions in liquid [86, 97, 121]. Moreover, initial recombination is
affected by applied voltage and thus leads to a dependency of the general recombina-
tion efficiency upon the applied voltage. Pardo-Montero and Gomez [98] developed
and verified a three voltage method as well as a modified two voltage method to
determine charge collection efficiency in parallel plate liquid ionization chambers.
We contribute to these investigations a detailed analysis of recombination effects
in several air-vented ionization chambers as well as one liquid ionization chamber
using pulsed high dose rate photon beams without flattening filter. This paper is
the first systematic study of the performance of ionization chambers with an FFF
accelerator commissioned for clinical use. Earlier investigations have been limited to
high dose per pulse electron beams [14]. While the clinical use of the FFF is rapidly
increasing [111] detailed studies regarding the behaviour of commonly used detectors
in conjunction with these beams are lacking. The beam pulse pattern of both FFF
and flattened beams were analyzed to show the influence of dose rate, dose per pulse
and pulse repetition frequency on collection efficiency. Detectors used for reference
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as well as relative dosimetry were investigated to ensure that depth dose curves and
profiles were not distorted due to insufficient charge collection within high dose rate
regions.
3.3 Materials and Methods
3.3.1 Linear accelerator and beam characteristics
Experimental data was collected using a Varian TrueBeam® linear accelerator (Var-
ian Medical Systems, Paulo Alto) at nominal energies of 6 MV and 10 MV with and
without flattening filter in the beam path (X6, X10 and X6FFF, X10FFF, respec-
tively). Characteristics of the four beams have been previously described in detail
by Hrbacek et al [53]. For X6 and X10 beams, dose rates between 1 Gy/min and 6
Gy/min (dmax, SSD= 100 cm, 10x10 cm2) are clinically available. By comparison
X6FFF allows dose rates between 4 Gy/min and 14 Gy/min, while X10FFF allows
dose rates between 4 Gy/min and 24 Gy/min (dmax, SSD= 100 cm, 10x10 cm2).
Table 3.1 summarizes the parameters regarding the beam pulse pattern of the four
Table 3.1: Basic characteristics of the beam pulse pattern for the four beams avail-
able on TrueBeam® linear accelerator (Varian). Dose rate (DR) (measured at the
depth of maximum dose (dmax), SSD = 100 cm and for field size of 10x10 cm2),
Dose rate (measured for a 40x40 cm2 field at SSD = 90 cm and dmax), time between
two pulses (∆t) and DPP (40x40 cm2, SSD = 90 cm, dmax) were measured using
delta4® phantom (ScandiDos, Sweden). For X6 and X10 the pulses come regularly
(every 2.78 ms @maximum dose rate), however for X6FFF and X10FFF every forth
to fifth pulse is dropped
Energy DR DR (40x40) ∆t DPP in dmax
(Gy/min) (Gy/min) (ms) (mGy)
X10FFF 4.0-24.0 5.3-31.9 16.7 - 2.8 1.7
X6FFF 4.0-14.0 5.6-21.6 9.7 - 2.8 1.1
X6 1.0-6.0 1.4-8.6 16.7 - 2.8 0.4
X10 1.0-6.0 1.4-8.4 16.7 – 2.8 0.4
energies at respective minimum and maximum dose rates. Dose per pulse (DPP)
and pulse repetition frequency (PRF) were measured with the delta4® phantom
(ScandiDos, Uppsala). At maximum dose rate PRF was equal for all beams. The
increased dose rate of FFF beams is due to the increased DPP relative to flattened
beams. Reduction of the dose rate is achieved within the TrueBeam system by
changing the PRF, whilst maintaining the same DPP. For X6 and X10, pulses are
generated at regular intervals (every 2.8 ms at maximum dose rate). For X6FFF
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and X10FFF however, every forth to fifth pulse is omitted. Therefore for X6 and
X10 DR, DPP and PRF can be related but not for the FFF beams.
3.3.2 Detectors under investigation
The general ion collection efficiency at different DPP and PRF was determined for
six ionization chambers in total:
 PTW 34001 Roos chamber
 PTW 34045 Advanced Markus Chamber
 PTW 31010 Semiflex chamber
 PTW 31016 PinPoint chamber
 PTW 30013 Farmer chamber
 PTW 31018 microLion chamber, liquid ionisation chamber
. Details on the chambers, provided in the manuals of the vendor (PTW, Freiburg),
are summarized in table 3.2.
Table 3.2: Basic specifications of the chambers (PTW, Freiburg) investigated: 4 dif-
ferent thimble (t) chambers and 2 plane-parallel (pp) chambers. Chambers differed
in terms of active volume, applied voltage and geometry. The microLion chamber
is filled with liquid isooctane. All other chambers are vented and respectively filled
with air.
chamber type active operating charge collection
volume (cm3) voltage (V) time (ms)
31010 Semiflex t 0.125 400 0.1
31016 PinPoint t 0.016 400 0.06
34001 Roos pp 0.35 200 0.125
34045 AdvMarkus pp 0.02 300 0.022
30013 Farmer t 0.6 400 0.14
31018 MicroLion t/liquid 0.002 800 5.3
3.3.3 Ion collection efficiency for gas filled chambers
According to Boag [11] the ion collection efficiency of an air vented ionization cham-
ber in pulsed beams can be expressed as:
f = u−1 ln(1− u) (3.1)
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u = µρ
d2
V
. (3.2)
(µ is a constant involving the ion recombination coefficient and mobilities, ρ is
the pulse charge density, d the equivalent electrode spacing and V the polarizing
voltage). For small charge densities this formula can be expanded up to the first
order term, which leads to a description of the saturation correction:
kS =
1
f
= 1 +
µ
2
ρ
d2
V
(3.3)
For chambers that follow this relation the saturation coefficient kS can be determined
using Boag’s two voltage method [12]:
kS =
V1
V 2
− 1
V1
V 2
− Q1
Q2
(3.4)
V1 is the operating voltage and V2 an arbitrary voltage (smaller than the operating
voltage), Q1 and Q2 are the collected charges at these voltages. We determined
the correction factors for all air vented filled ionization chambers according to this
formula. The operating voltages V2 for the chambers can be found in table 2. V2
was chosen to be half of V1, as recommended by Almond et al [4]. All measurements
were performed for a geometry, which maximizes dose rate, i.e. shortest SSD (90
cm) (within commissioning relevant limits), largest field size 40 x 40 cm2), and at
the depth of maximum dose. The dose corresponding to 100 MU was:
 1.40 Gy @ depth of 1.21cm for X6FF
 1.33 Gy @ depth of 2.10 cm for X10FFF
 1.46 Gy @ depth of 1.43 cm for X6
 1.40 Gy @ depth of 2.23 cm for X10.
This resulted in a DPP of 1.1 mGy for X6FFF, 1.7 mGy for X10FFF, 0.4 mGy for
X6 and 0.4 mGy for X10. The dependency of ion collection efficiency upon PRF,
DPP and beam energy was studied.
3.3.4 Ion collection efficiency for liquid ionization chambers
In liquid ionization chambers the influence of initial recombination cannot be ne-
glected. The charge released within the chamber is dependent upon the applied
voltage. If DPP is low and the time between pulses is longer than the ion collec-
tion time of the chamber, the collected charge Q, will relate linearly to the applied
voltage V [98]:
Q = Q0(1 + c · V ) (3.5)
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We determined the coefficients c and Q0 at PRF less than 100 Hz and a DPP of
0.03 mGy (SSD = 120 cm, depth = 25 cm, X6 and X10). According to the modified
2-voltage method of Pardo-Montero and Gomez [98], which is valid so long as the
ion collection time is small relative to the time between two consecutive pulses, the
ion collection efficiency can be determined as follows:
f =
(1 + cV2)
2V1Q1 − (1 + cV1)(1 + cV2)V2Q1
(1 + cV2)2V1Q1 − (1 + cV1)2V2Q2
(3.6)
According to this method we determined the collection efficiency of the liquid ion-
ization chamber for all four beams at the lowest available PRF (time between two
pulses > ion collection time of 5.3 ms). For higher PRF the relative collection ef-
ficiency compared to the Markus chamber was determined. The ratio of reading
between the liquid filled chamber and the Markus chamber was compared for differ-
ent doses per pulse. Dose per pulse was changed by varying the measurement depth
(2 cm to 30 cm) as well as the SSD (SSD=90 cm and SSD=120 cm). The collection
efficiency of the Markus chamber was above 0.994 (shown in the first part of the
results) and therefore neglected for the relative comparison to the liquid ionization
chamber. For the lowest dose per pulse (SSD = 120 cm, depth = 30 cm) the ratio
was set to 1, as it is known that the collection efficiency is high (above 0.995) for a
dose per pulse below 0.3 mGy [119].
3.3.5 Propagation of uncertainty
Q1 and Q2 were measured multiple times and mean values and standard deviations of
the mean uQ1 and uQ2 were calculated. Using uncertainty propagation the standard
deviation for the ion collection efficiency uf was calculated according to:
uf =
√
df
dQ1
2
uQ1 +
df
dQ2
2
uQ2 (3.7)
3.4 Results
3.4.1 Ion collection efficiency for air-vented chambers
Table 3.3 summarizes ion collection efficiency factors of all investigated air-vented
chambers for all four beams. The collection efficiency was above 0.985 (2uf = 0.002)
in all cases. The Markus chamber demonstrated the largest collection efficiency 0.994
(2uf = 0.002) for X10FFF; 0.997 (2uf = 0.001) for X6 and X10). The collection
efficiency was independent of pulse repetition frequency (figure 3.1), implying that
for a given beam with specific DPP the collection efficiency does not change with
dose rate. The collection efficiency corrections for 6 MV and 10 MV beams did not
significantly differ. Figure 3.2 shows the relationship between ion collection efficiency
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Table 3.3: Ion collection efficiencies of the five air-vented ionization chambers (PTW,
Freiburg) at depth of maximum dose, field size 40 x 40 cm2 and SSD = 90 cm. Two
standard deviations are given in brackets.
Chamber X6 X10 X6FFF X10FFF
(DPP=0.4mGy) (DPP=0.4mGy) (DPP=1.1mGy) (DPP=1.7mGy)
Semiflex 0.995 (0.003) 0.995 (0.001) 0.991 (0.001) 0.988 (0.001)
PinPoint 0.991 (0.001) 0.992 (0.001) 0.990 (0.002) 0.990 (0.003)
Farmer 0.997 (0.001) 0.997 (0.002) 0.992 (0.001) 0.989 (0.002)
AdvMarkus 0.999 (0.001) 0.999 (0.001) 0.998 (0.001) 0.994 (0.002)
Roos 0.997 (0.001) 0.996 (0.001) 0.992 (0.001) 0.986 (0.002)
and DPP; the collection of charge became less efficient with increasing DPP (table 1
shows DPP for the four beams). Extrapolating the linear fit of the data to zero shows
the initial recombination of all chambers below 0.2 % (2uf = 0.1%), except for the
pinpoint chamber which generated an initial recombination of 0.87 % (2uf = 0.2%).
3.4.2 Ion collection efficiency for liquid filled chambers
The coefficient c which describes the relationship between produced charge and
applied voltage (equation 4) was determined to be 0.001123V −1 (u = 3.30·10−5V −1).
Figure 3.3 shows the relationship between DPP and collection efficiency for both
methods. The collection efficiency was seen to decrease with increasing DPP and
PRF. Both methods show comparable results. Collection efficiency for flattened
beams was above 0.99. With increasing DPP, the collection efficiency decreases to
approximately 0.96 for the X10FFF at low PRF and 0.94 at high PRF (both DPP
= 1.7 mGy).
3.5 Discussion
3.5.1 Ion collection efficiency for air vented chambers
Our results confirm that air vented chambers can be used for relative dosimetry of
FFF beams without correction for collection efficiency. When applied for the refer-
ence dosimetry, a collection efficiency of 0.991 (for X10FFF) and 0.998 (for X6) was
found for the Farmer chamber at the reference geometry (SSD=100 cm, depth=10
cm, field size 10x10 cm2). For the pinpoint chamber, a low ion collection coefficient
for all four beams was found as well as a very high initial recombination factor.
Agostinelli et al [3] reported for the PinPoint chamber (PTW 31014), that the sat-
uration curve was not linear above 150 V. Therefore, the two-voltage method leads
to an underestimation of the collection efficiency by approximately 0.5 % (for an
applied voltage of 400 V). The design of the two PinPoint chambers PTW 31014
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Figure 3.1: Dependency of collection efficiency on pulse repetition frequency when
using the Farmer chamber (PTW, Freiburg). The time between pulses (dt) was
altered by varying the dose rate of the X10FFF beam between 2400 MU/min (dt =
2.78 ms) and 400 MU/min (dt = 16.67 ms).
and PTW 31016 is very similar. It is therefore likely that the PTW 31016 chamber
operated at 400 V was also within the non-linear region and collection efficiency
using the two-voltage method was underestimated.
Results obtained for the collection efficiency of the Roos and Farmer chamber are in
a good agreement with those published by Bruggmoser et al [14]. Their calculated
collection efficiency of 0.985 in pulsed electron beams (for a DPP of 1.7 mGy) cor-
responds with our measurement of the X10FFF beam. The collection efficiency for
doses per pulse of 1.1 mGy, 0.41 mGy and 0.39 mGy were determined to be 0.990,
0.996 and 0.9965, respectively, by Bruggmoser et al [14]. Similarly, we found 0.992
(X6FFF, DPP = 1.1 mGy), 0.996 (X6, DPP = 0.4 mGy) and 0.9965 (X10, DPP
= 0.4 mGy)). Using the Farmer chamber, Bruggmoser et al [14] published slightly
lower collection efficiencies (0.981 @ DPP = 1.7 mGy, 0.989 @ DPP = 1.1 mGy and
0.9955 @ 0.41 mGy). However, a different polarizing voltage was applied (300 V
rather than 400 V).
3.5.2 Ion collection efficiency for liquid filled chambers
The microLion chamber had an ion collection efficiency of 0.94 when exposed to the
X10FFF beam at maximum dose rate. Ion collection efficiency correction should
therefore be applied for both reference and relative dosimetry. Lowering of the dose
rate increased the ion collection efficiency because the time between pulses became
long enough for the pulses to be fully collected. Measuring depth dose curves of a 10
x 10 cm2 field (X10FFF, DR 24 Gy/min), the collection efficiency varied from 0.941
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Figure 3.2: Ion collection efficiency decreases linearly with increasing dose per pulse
for the Farmer chamber, SemiFlex chamber and Roos chamber (all PTW, Freiburg).
(X10FFF : DPP = 1.73 mGy, X6FFF: 1.08 mGy, X6: 0.4 mGy and X10: 0.39 mGy).
at the depth of maximum dose to 0.977 at 30 cm depth. Normalising the beam
to the dose maximum, as is common practise, leads to an overestimation of dose
in the tail region of the depth dose curve. This discrepancy increased with depth.
Most liquid filled ionization chambers described in the literature have a larger active
volume [60, 61] or use a different liquid [22] than the MicroLion chamber. A similar
chamber design was evaluated by Steward et al [119]. For a 6 MV beam with
dose rate of 1 Gy/min and DPP of 0.36 mGy, a collection efficiency of 0.995 was
determined. This is in agreement with our result (0.996 (u = 0.005)). Wickman
and Nystro¨m [133] reported a collection efficiency of 0.9945 for pulsed radiation at
a PRF of 100 Hz, which reduced to 0.992 when the PRF was increased to 200 Hz.
In our study, a similar reduction was observed when the PRF was increased to 330
Hz.
3.6 Conclusion
Five commonly used air vented ionisation chambers were investigated to determine
their collection efficiency in high dose rate and high dose per pulse flattening filter
free photon beams. For all chambers collection efficiency was above 0.986 and can
therefore be used reliably for relative dosimetry. The Markus chamber demonstrated
the largest ion collection efficiency (0.994 @ DPP = 1.7 mGy, X10FFF beam). The
order of correction for reference dosimetry is given within the manuscript. Addi-
tionally, the performance of the iso-octane filled MicroLion chamber was tested. Ion
collection efficiency for flattened beams was above 0.99 for both investigated beams
at all dose rates. However, we observed a relatively low collection efficiency of 0.960
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Figure 3.3: Relative ion collection efficiency of the microLion chamber (PTW,
Freiburg) for the four beams at different dose rates (DR) decreases with increas-
ing dose per pulse. The results obtained using the modified two voltage method
agree well with the relative measurements (compared with advanced Markus cham-
ber, PTW).
for the X10FFF beam at a dose rate of 5.32 Gy/min. Increasing the dose rate to
31.9 Gy/min further decreased the collection efficiency to 0.940. It is therefore not
advisable to use this chamber for flattening filter free depth dose curve measure-
ments.

Chapter 4
The use of photon beams of a
flattening filter-free linear
accelerator for hypofractionated
volumetric modulated arc therapy
in localized prostate cancer∗
4.1 Abstract
Purpose: To evaluate the potential usage of flattening filter-free (FFF) photon
beams in the treatment of prostate cancer.
Methods and Materials: Volumetric modulated arc therapy (VMAT) treatment
planning was performed for seven patients using TrueBeam® linear accelerator and
photon beams with (X6, X10) and without (X6FFF, X10FFF) flattening filter. Pre-
scribed dose was 19 x 3 Gy = 57 Gy. One or two 360° arcs with dose rate of 600
MU/min for flattened beams, and 1200 MU/min for FFF beams were used.
Results: No difference was detected between the four beams in PTV coverage,
conformity and homogeneity. Mean body dose and body volume receiving 50% of
the prescribed dose decreased with increasing mean energy (R2 = 0.8275, p < 0.01).
X6FFF delivered 3.6% more dose compared to the X6 (p < 0.01). X10FFF delivered
3.0% (p < 0.01), and the X10 5.8% (p < 0.01) less mean body dose compared to
X6. There was a significant increase in the mean dose to the rectum for the X10
compared to X6 (2.6%, p < 0.01). Mean dose to the bladder increased by 1.3% for
X6FFF and decreased by 2.3% for X10FFF. Using a single arc and FFF, treatment
time was reduced by 35% (2SD = 10%).
Conclusion: FFF beams resulted in dose distributions similar to flattened beams.
∗This chapter has been published in International Journal of Radiation Oncology* Biology*
Physics, Vol. 83, No. 5, August 2012 (Zwahlen et al [139]).
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X10FFF beam provided the best solution, sparing rectum and bladder and mini-
mizing whole body dose. FFF beams lead to a time efficient treatment delivery,
particularly when combined with hypofractionated VMAT.
4.2 Introduction
The possibility of a low α\β -ratio for prostate cancer provides a radiobiological ad-
vantage for hypofractionated radiation therapy (RT) with excellent local control and
low toxicity [109]. Intensity modulated RT (IMRT) and volumetric modulated arc
therapy (VMAT) are used to reduce doses to bladder and rectum while maintaining
optimised dose coverage and conformity of the planning target volume (PTV) [113].
Compared to 3D conformal RT (3DCRT) these highly conformal treatments require
more monitor units (MU) and increased treatment time. There is also increased
leakage and scatter dose from the linear accelerator (LINAC) multileaf collimator
(MLC) outside the treatment volume resulting in a higher whole body dose [47].
Increasing head shielding and removing the flattening filter reduces head leakage
and scatter. Removal of the flattening filter reduces number of photon interactions
within the gantry and increases dose delivery efficiency [125].
TrueBeam® STx (Varian Medical Systems, Paolo Alto, CA, USA) is a new platform
of LINAC designed to deliver flattened, as well as flattening filter-free (FFF), beams
[53]. Historically, the flattening filter provided a relatively flat beam profile over
the entire treatment field and dose distributions was calculated in a simplified way.
With beam intensity modulated techniques, including IMRT and VMAT, the MLC
is used to modify the fluence distribution producing optimal fluence maps for FFF
beams similar to those with flattening filter [125, 126]. Interest in FFF technology is
resulting from the expectation that it will allow faster treatment delivery with dose
rates up to 24 Gy/min [38].
Several studies summarised the properties of FFF beams of various LINACs based
on Monte Carlo simulations or dosimetric measurements [53, 126, 20, 40, 65, 118].
Few studies investigated the feasibility of using FFF beams for IMRT treatment
planning [20, 118, 123, 124]. The studies were performed for prototype LINAC and
treatment planning systems with pre-clinical release and showed comparable IMRT
dosimetric plan quality for FFF compared to flattened beams.
This is the first treatment planning study investigating hypofractionated VMAT
with 6 MV and 10 MV FFF photon beams in a clinically released setting for pa-
tients with localised prostate cancer.
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4.3 Materials and Methods
4.3.1 Patient selection and contouring
Planning study included the computed tomographies of seven patients with local-
ized prostate cancer. After ethics approval, men were treated in the CHHiP trial
(Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy
for Prostate Cancer, The Institute of Cancer Research, Sutton, Surrey, UK) at the
University Hospital Zurich. Patients were randomized between conventional radia-
tion therapy (74 Gy in 37 fractions) and the experimental groups of 60 Gy in 20
fractions and 57 Gy in 19 fractions (treating 5 days per week) [23]. Patients were
treated with RapidArcrplans and 6 MV flattened beams in 2010.
Contouring of target volumes and organs at risk (OAR) was performed using the
CHHiP protocol, version 8 [23]. Gross tumour volume (GTV) included the prostate
only. Clinical target volume (CTV) 1 included prostate and base of seminal vesicles
(proximal 2 cm) with 5 mm margin or prostate and seminal vesicles with 5 mm
margin for patients with risk of seminal vesicle involvement. CTV 2 encompassed
prostate only with 5 mm margin. CTV 3 included prostate only. PTV 1 to 3 added
a 5 mm margin to the relevant CTV, except that for PTV 2 and 3 there was 0 mm
margin posteriorly or posterior inferiorly. OARs outlined included bladder, rectum,
bowel, femoral heads, urethral bulb and skin. Generated PTV and OAR volumes
are summarized in Table 4.1.
Table 4.1: Volumes for planning target volumes, organs at risk, and dose constraints
Volume Mean (+/- 1 SD) (ccm) Range (ccm) Dose constraints
PTV 1 202.5 (+/- 29.0) 149.0 - 238.2 V99% ≥ 76% of PD, mean (PTV1-PTV2) ≥ 80% of PD
PTV 2 136.1 (+/- 31.5) 101.3 - 198.3 V99% ≥ 91% of PD, mean (PTV1-PTV2) ≥ 96% of PD
PTV 3 75.3 (+/- 16.1) 56.3-104.1 V99% ≥ 95% of PD, V99% < 105% of PD
Rectum 129.9 (+/- 31.3) 134.7 - 334.0 V68% ≤ 60%, V81% ≤ 50%, V95% ≤ 15%, V100% ≤ 3%
Bladder 253.6 (+/- 68.8) 107.9 - 198.9 V68% ≤ 50%, V81% ≤ 25%, V100% ≤ 5%,
Urethral bulb V68% ≤ 50%, V81% ≤ 10%
Femoral heads V68% ≤ 50%
Bowel V68% ≤ 17 mL
4.3.2 Photon beams
Treatment planning was performed using four photon beams of TrueBeam® STx
LINAC. Beams with nominal energies of 6 MV and 10 MV with flattening filter
in the beam path (X6 and X10) and FFF beams (X6FFF, X10FFF) were investi-
gated. Detailed description of these beam characteristics is reported elsewhere [53].
Removal of the flattening filter had several implications on the beam properties in-
cluding a non-flat beam profile, an increase in maximal dose rate of up to 14 Gy/min
for X6FFF and 24 Gy/min for X10FFF as well as a decrease in mean radial energy
(TPR20/10: X6 0.667, X6FFF 0.631, X10 0.738, X10FFF 0.692) as there was no
beam hardening. As a measure of beam energy, the beam quality index TPR20/10
(ratio of the tissue phantom ratio at 20 cm and 10 cm) was used.
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4.3.3 Treatment planning
Prescribed dose was 19 x 3 Gy = 57 Gy. Four VMAT plans (RapidArc®) were cal-
culated for each patient using the Eclipse® External Beam Planning System (PRO
8.9, AAA 8.9, Varian Medical Systems). The plans were normalized that PTV3 re-
ceived a mean dose of 100% of the prescribed dose. Dose constraints were specified
in the CHHiP trial protocol [23] and are reported in Table 4.1. One 360° arc (n =
3) was used to fulfil the constraints with maximum dose rate of 600 MU/min for
flattened beams and 1200 MU/min for unflattened beams. A second arc (n = 4)
was added in case constraints could not be met. For plans using one arc, collimator
angle was 45°. Using two arcs separation in collimator angle was 90°. Objectives for
OAR were interactively lowered during optimisation for X6 beams without compro-
mising target coverage. After achieving a satisfactory set of constraints, plans for
all four energies were optimized using these constraints. Final dose calculation was
performed with Eclipse® AAA 8.9 algorithm and a calculation grid size of 2.5mm.
4.3.4 Plan evaluation and statistical methods
Plan evaluation was performed according to the CHHiP trial protocol [23]. MU,
mean body dose, surface dose (cumulative dose in the first 2 mm of the body), mean
doses to rectum and bladder, conformity index (volume enclosed by the prescription
isodose / target volume) of PTV 1, ratio of volume receiving 50% of dose to PTV 1
and treatment time were recorded.
Plans using X6FFF, X10FFF and X10 beams were compared to the X6 base plan
and ratios of acquired dosimetric parameters recorded.
Statistical analysis was performed with MATLAB®, version 7.6, software (Math-
Works, Natick, MA, U.S.A.). Mean values and standard deviation of the mean
(SD) were collected. Relative dosimetric changes were compared applying the non-
parametric Wilcoxon signed-rank test. A two-sided p value of 0.05 was considered
statistically significant. Confidence intervals (CI) included 95% of the measured
data. Box-Whisker-Plots were created for selected data, showing ratios of X6FFF,
X10FFF and X10 beams to X6 beam.
4.4 Results
4.4.1 Dose distribution and PTV coverage
For all treatment plans, there were only minor differences in dose distributions using
X6FFF, X10FFF, X10 and X6 beams. No difference was detected between the four
beam qualities with respect to PTV coverage and conformity. Target inhomogeneity
was increased by 1% for X6FFF and X10FFF beams compared to flattened beams
(Fig. 4.1), and below the expected specification of 10% (Table 4.2).
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Figure 4.1: PTV inhomogeneity (defined as Dmax-Dmin in PTV3) for the four
different energies. Inhomogeneity is increased for FFF beams.
Table 4.2: Dosimetric parameters for the plans using the four different beam modal-
ities: MU, dose parameters, and beam-on time (mean +/- 1 SD). The beam-on time
included patients treated with one and two arcs.
X6 X6FFF X10 X10FFF
Number of Mus 897 (+/- 202) 951 (+/- 141) 718 (+/- 88) 896 (+/- 133)
Mean body dose (Gy) 8.52 (+/- 2.40) 8.83 (+/- 2.46) 8.06 (+/- 2.36) 8.27 (+/- 2.32)
Mean dose to rectum (Gy) 55.6 (+/- 3.6) 55.7 (+/- 3.2) 57.0 (+/- 3.8) 55.6 (+/- 4.11)
Mean dose to bladder (Gy) 36.2 (+/- 7.7) 36.7 (+/- 8.0) 36.0 (+/- 8.3) 35.5 (+/- 8.0)
Conformity PTV 1 1.38 (+/- 0.11) 1.39 (+/- 0.12) 1.38 (+/- 0.12) 1.38 (+/- 0.13)
Inhomogeneity PTV 3 7.1 ( +/-0.99) 7.9 (+/-0.85) 6.9 (+/-0.78) 7.6 (+/-1.51)
Beam-on time (min) 1 min, 47 sec 1 min, 34 sec 1 min, 43 sec 1 min, 34 sec
4.4.2 Monitor units and mean body dose
The mean body dose decreased significantly with increasing mean energy of the
beam (R2 = 0.8275, p < 0.01) (Fig. 4.2). X6FFF beam delivered 3.6% more dose
compared to the X6 beam (p < 0.01, CI = 2.2% - 4.9%). X10FFF beam delivered
3.0% less dose (p < 0.01, CI = -2.3% - -4.7%) and the X10 beam 5.8% less dose (p
< 0.01, CI = -3.8% - -7.8%). The volume receiving 50% of the prescribed dose to
PTV 1 decreased significantly with increasing mean energy (Fig. 4.3).
MU significantly increased for X6FFF by 7.7% (p < 0.02, CI = 0.8% - 16.5%),
and for X10FFF by 1.2% (p = 0.7, CI = - 8.2% - 9.8%), however increase was not
significant. A significant decrease of 18.8% (p < 0.02, CI = -4.7% - -30.9%) in MU
for X10 was detected due to the higher mean energy (Table 4.2).
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Figure 4.2: Mean body dose dependence on the beam quality. Body dose was
normalized to mean body dose of X6 beam.
4.4.3 Dose to skin and organs at risk
Compared to X6 beam, the mean skin dose significantly increased by 8.2% (p <
0.01, CI = 5.9% - 11.3%) for X6FFF beam and decreased significantly by 9.1 %
(p < 0.01, CI = -7.8% - -11.7%) and 12.9% (p < 0.01, CI = -9.9% - 14.1%) for
X10FFF and X10 beams. There was no difference in mean dose to the rectum and
dose parameters V68%, V81%, V95%, V100% were not statistically different for X6,
X6FFF and X10FFF beams (Table 4.2). A significant increase in mean dose of 2.6%
(p < 0.01, CI = 0.6% - 4.2%) to the rectum was measured for X10 compared to X6
beam energy. The mean dose to the bladder was increased significantly by 1.3% for
X6FFF (p < 0.02, CI = -0.1% - 2.2%) and decreased significantly by 2.3% (p <
0.02, CI = -0.2% - 3.7%) for X10FFF; no significant changes were detected for X10
(Table 4.2).
For the urethral bulb there was no difference for V68% and V81% with respect to
the four beams, and V68% for bowel and femoral heads were within the required
constraints for all patients and beam energies.
4.4.4 Treatment time
For plans using a single arc, treatment time was significantly reduced to one minute
when using X6FFF and 10XFFF beams. The mean treatment time for single arc X6
and X10 plans were 1 minute 30 seconds and 1 minute 25 seconds (Table 4.2). The
higher maximum dose rates for FFF beams allowed the gantry to run at maximum
speed during the full arc. For flattened beams the gantry had to slow down in order
to deliver the necessary MU. There was no difference in treatment time if two arcs
were used.
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Figure 4.3: Box-Whisker-Plots for different dose parameters. Ratio of X6FFF (top),
X10FFF (middle), X10 (bottom) with X6. The red line represents the median value,
the blue box the interquartile range and the whiskers minimum and maximum.
4.5 Discussion
The results of this planning study demonstrated that with hypofractionated VMAT
dose distribution, conformity and homogeneity within the PTVs were similar using
either flattened or unflattened 6 and 10 MV photon beams. We showed that the
mean body dose was a function of beam energy and decreased with increasing mean
energy. Absence of the flattening filter resulted in a 3.6% higher mean body dose for
X6FFF compared to X6 beams. X10FFF decreased the mean body dose by 3% com-
pared to the X6 beam; however, it increased the mean body dose by 2.8% compared
to X10. For the rectum, mean organ dose increased for the 10 MV-unflattened pho-
ton beam compared to the 6 MV beams. Interestingly, usage of X10FFF decreased
mean bladder dose compared to the other three beam qualities. Finally, with FFF
technology treatment time for a single arc was significantly reduced due to increased
dose rate and faster delivery time.
Ensuring high quality 3DCRT, homogeneous photon fluence across the treatment
field is of high priority to achieve optimal PTV coverage. A flattening filter was
needed to ensure homogeneous target coverage. With the introduction of MLC
changing leaf positions across the field modulate photon fluence to achieve optimal
fluence maps [126, 118]. A uniform beam is no longer necessary as comparable treat-
ment planning results for either flattened or unflattened beams have been reported
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[38], in particular for smaller treatment fields used in extracranial stereotactic RT
for lung cancer [123]. Vassiliev et al. [123] reported in their planning study using
6 and 18 MV IMRT, with and without flattening filter, similar treatment plans re-
garding PTV coverage for prostate cancer. Depending on the beam energy, X6FFF
produced superior IMRT plans than X6. X18FFF resulted in inferior plans com-
pared to X18 due to larger differences between optimal and deliverable fluence maps
when compared to 6 MV [124]. However, plans and treatment delivery parameters
were not fully optimized for FFF beams and the authors state that improvement of
PTV coverage for either plan might have been possible with different user-specific
cost functions for either the PTV or organs at risk. Similarly, Stathakis et al. ob-
served negligible differences in PTV coverage between flattened and FFF 6 and 18
MV IMRT prostate plans. As expected, our data confirmed the authors finding that
superficial dose was decreasing with increasing mean energy [118]. Compared to our
study both groups [118, 124] implemented IMRT techniques with FFF beams on
a non-clinical prototype LINAC. Using VMAT technique, we found similar results:
PTV coverage was unchanged using flattened or unflattened beam. However, we
could detect a small difference of 1% in PTV inhomogeneity for FFF beams (Fig.
4.1). At this stage, it is unknown if the measured target inhomogeneity has any
clinical relevance for treatment outcome of future patients with localized prostate
cancer. Applying tighter objectives in the planning optimization process may re-
duce target inhomogeneities. However we designed our study keeping all treatment
planning objectives constant for all four beam energies.
For flattened beam intensity modulation treatments, including IMRT and VMAT,
the number of MU needed is an indicator for the mean body dose [36]. We found
that a higher number of MU for FFF beams compared to flattened beams did not
necessarily lead to an increased mean body dose. Due to the non-flat profile of the
FFF beam, the integral dose of open fields in a water phantom is smaller than for a
flattened beam in relation to 100 MU (Fig. 4.4). This finding was more pronounced
with increasing field size. Therefore, compared to X6 an increase in MU for FFF
beams was expected. Indeed, the planning study showed that the number of MU
increased for X6FFF and X10FFF by 7.7% and 1.2%. In contrary, Vassiliev et al.
[124] as well as Stathakis et al. [118] found a significant decrease in the number of
MU for their FFF treatment plans. The reason was that our FFF beams were cali-
brated in order that 100 MU corresponded to 1 Gy at the depth of maximum dose, as
this was common for flattened beams [4]. However, for all prototype LINACs with
FFF capabilities used by other groups, only the flattened beams were calibrated.
This resulted in a higher dose per 100 MU for the unflattened beams. Therefore
they report a decrease in number of MU that we could not confirm in our study.
Our data demonstrated that the mean body dose slightly decreased with the mean
energy of the beam, despite the increase in number of MU that did not impact on
the mean body dose.
Use of beam modulating techniques exposes the whole body to a larger amount of
scattered low dose radiation as significant parts of treatment fields are being blocked
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Figure 4.4: Integral dose of open fields in a water phantom relative to X6 beam
corresponding to 100 MU for different field sizes.
by the MLC increasing MU and scatter dose [113]. Prostate cancer patients treated
with IMRT might be exposed to a 2-fold increased risk of developing secondary ma-
lignancies compared to 3DCRT [113]. It is expected that FFF beams compared to
flattened beams deposit less dose outside the target volume due to the missing scat-
ter from the flattening filter and the reduced head scatter [20, 124, 66, 67]. Kragl et
al. demonstrated that using FFF beams for IMRT prostate treatments resulted in a
reduction of treatment head leakage by 52% and 65% for 6 and 10 MV, respectively
[66]. Similarly, Cashmore et al. found in their study that IMRT using FFF beams re-
moved unwanted and unnecessary scatter dose from the treatment head and lowered
peripheral dose by up to 70% [20]. Applying hypofractionated treatment regimens
for localized prostate cancer, treatment delivery time is important. With flattened
beams and a limited output of MU/min higher dose per fraction leads to longer
beam-on time and organ motion becomes relevant [52]. We found a time advantage
for both FFF beams compared to X6 beam if one arc was used for planning. If the
gantry was running at maximum speed, the time needed for one arc was one minute.
Flattened beams can deliver in one minute 600 MU, X6FFF 1400 MU and X10FFF
2400 MU. Therefore, whenever more than 600 MU per arc are needed, FFF beams
reduce treatment time compared to flattened beams. The number of MU needed for
the seven patients ranged between 564 MU to 803 MU (for X10) and 803 MU to 1283
MU (for X6). For FFF beams the number of MU was slightly increased. Therefore
there is a time advantage for both FFF beams compared to X6 beam if one arc is
used for planning. Fu et al. found a time advantage for FFF IMRT treatments
of 46% depending on the dose per fraction. The time advantage increased when
using higher dose per fraction, however was insignificant for standard fractionation
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of 2 Gy [38]. For sliding window IMRT the potential benefit of high dose rate is
limited by the speed of the MLC. For treatments with RapidArc® gantry speed
is the limiting factor. This study has several limitations. Our findings were based
on a planning, rather than a clinical study. It is known that treatment planning
systems do not correctly model the low dose region [49]. Therefore the expected
advantage of FFF beams to reduce the dose outside the target volume is not shown
in our planning study. At the present time, our results may be interpreted as hav-
ing theoretical value rather than showing a clinical benefit for patients. However,
this study revealed that non-inferior VMAT plans could be generated to deliver fast
and high quality hypofractionated RT. We acknowledge the relevance and impor-
tance of image-guidance for modern prostate cancer radiotherapy when combining
hypofractionated VMAT, high dose rate and fast delivery time due to organ motion;
however, this was beyond the scope of this paper. Finally, as we carefully analysed
the differences and their impact on treatment planning and delivery, we believe our
study contributes to a better understanding of the differences between flattened and
unflattened beams in future clinical use.
Chapter 5
Pretreatment quality assurance of
flattening filter free beams on 224
patients for intensity modulated
plans: A multicentric study ∗
5.1 Abstract
Purpose: Pretreatment quality assurance data from four centers, members of the
European TrueBeam council were analyzed with different verification devices to
assess reliability of flattening filter free beam delivery for intensity modulated radio-
therapy (IMRT) and RapidArc (RA) techniques.
Methods: TrueBeam®(Varian Medical System) is a new linear accelerator de-
signed for delivering flattened, as well as flattening filter free beams. Pretreatment
dosimetric validation of plan delivery was performed with different verification de-
vices and responses to high dose rates were tested. Treatment planning was done
in Eclipse planning system (PRO 8.9, AAA 8.9). Gamma evaluation was performed
with (dose difference) = 3 % and (distance to agreement) = 3 mm scoring the gamma
agreement index (GAI, % of field area passing the test). Two hundred and twenty-
four patients with 1–6 lesions in various anatomical regions and dose per fraction
ranging from 1.8 Gy to 25 Gy were included in the study; 88 were treated with 6
MV flattening filter free (X6FFF) beam energy and 136 with 10 MV flattening filter
free (X10FFF) beam. Gafchromic films in solid water, DELTA4, ARCCHECK, and
MATRIXX phantom were used to verify the dose distributions. Additionally, point
measurements were performed using a PinPoint chamber and a Farmer chamber.
Results: Dose calculation as well as dose delivery was equally accurate for IMRT
and RA delivery (IMRT: GAI = 99.3% (+/-1.1); RA: GAI=98.8% (+/-1.1) as well as
∗This chapter has been published in Medical Physics, Vol. 39, No. 3, March 2012 (Lang et al
[70]).
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for the two beams evaluated (X6FFF: GAI = 99.1% (+/-1.0); X10FFF: GAI=98.8%
(+/-1.2). Only small differences were found for the four verification devices. A point
dose verification was performed on 52 cases, obtaining a dose deviation of 0.34%.
The GAI variations with number of monitor units were statistically significant.
Conclusions: The TrueBeam FFF modality, analyzed with a variety of verification
devices and planned with Eclipse planning system is dosimetrically accurate (within
the specified limits 3mm/3%) for both X6FFF and X10FFF beam energy.
5.2 Introduction
In the past, the flattening filter (FF) was introduced into the linear accelerator to
achieve a uniform profile over the entire field size. More recently, the introduction
of intensity modulated radiotherapy (IMRT) techniques makes a flat profile in many
cases redundant as the multileaf collimator (MLC) is used to reach the best possi-
ble dose distribution. TrueBeam®(Varian Medical System, Palo Alto, USA) is a
new accelerator designed for delivering both in FF and flattering filter free (FFF)
modality whose beam’s characteristics have recently been published in literature [53].
Removal of the filter leads to an increased dose rate [53], which is expected to reduce
treatment time, and consequently intrafractional motion. Fu et al [38] showed for
intensity modulated prostate and nasopharynx cases a reduction of beam on time of
43%. Additionally FFF beams are expected to reduce secondary malignancies due
to reduced MLC transmission, head scatter, and leakage radiation [53, 67, 66, 20].
Kragl et al [66] showed a 31% dose reduction 20 cm outside the treatment volume
for SBRT cases, 16% for prostate cases and 18% for head and neck cases for a 10 MV
FFF (X10FFF) beam compared to the FF beam. Cashmore et al. [20] investigated
out-of-field dose for paediatric IMRT showing a reduction of up to 70% for distant
organs. However, there are concerns regarding the safe delivery of FFF beams [39],
especially regarding the monitor chamber, which is used to steer the beam. The
signal produced in the monitor chamber is mainly due to the electrons generated in
the FF. In order to have enough signal for FFF beams a thin foil is introduced into
the beam path which was shown for prototype FFF accelerators in literature to give
sufficient electron signal for monitoring the beam [39, 118, 20].
Additionally the increased output of TrueBeam makes higher demands on the reac-
tion time of the servo system of the linear accelerator. Several studies demonstrated
the verification of dose calculation algorithm for FFF beams under physical condi-
tions (in a water phantom) [53, 118, 34] ; however, only little data are published on
the dose calculation of FFF IMRT and RapidArc (RA) fields [118, 20].
This manuscript describes an evaluation of multi-institute pretreatment quality as-
surance (QA) data to assess reliability of FFF beam delivery for IMRT and RA tech-
niques. Data from 4 centers [Instituto Clinico Humanitas (ICH), UniversityHospital
Zurich (USZ), KantonsSpital Winterthur (KSW), and Institut Catala‘ d’Oncologia
(IOC)] acquired with different verification devices were analyzed. The study demon-
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strates clinical reliability of FFF beam delivery and dose calculation offered by the
Varian TrueBeam system. Additionally the multicenter study allowed the use of a
variety of QA devices, giving the reader an overview of devices suitable for the use
in high dose rate flattening filter free photon beams.
5.3 Materials and Methods
Two hundred and twenty-four patients with 1–6 lesions in various anatomical re-
gions and dose per fraction ranging from 1.8 to 25 Gy were included in the study;
88 were treated with 6 MV FFF beam energy (X6FFF) and 136 with X10FFF
beams. Measurements were performed for plans of variable complexity: lung stage I
and lung metastases (76 cases), brain metastases and vestibular schwannoma (32),
spinal tumors (10), liver metastases (28), pancreatic lesions (15), mediastinal tu-
mors (12), prostatic cancer (12), and others (39). Gafchromicrfilms in solid water,
DELTA4r, ARCCHECKr, and MATRIXXrphantom were used to verify the dose
distributions (Table 5.1). Furthermore, for 27 patients, a PinPoint (PinPoint cham-
ber, PTW) dose verification was performed in solid water. A detailed summary of
type and number of plans verified by each institution can be found in Table 5.1.
Table 5.1: Number of plans verified by the different institutions; devices used: m:
Matrixx, gf: gafchromic film in solid water, d: delta4, a: ArcCheck.
ICH USZ KSW ICO total
Total 100 27*+ 52# 27 18 224
RA 100 19*+ 50# 27 18 214
IMRT 0 5*+ 5# 0 0 10
X6FFF 19 19*+ 36# 10 4 88
X10FFF 81 8*+ 16# 17 14 136
device m *gf + #d a a —
5.3.1 Linear accelerator and flattening filter free beams
All measurements were performed on TrueBeamVR linear accelerators using X6FFF
and X10FFF energy modes. FFF beams (on TrueBeam) have a lower mean energy,
an increased dose per pulse and an increased maximum dose rate compared to FF
beams [53]. Maximum dose rates of 2400 and 1400 MU/min can be achieved with the
X10FFF and the X6FFF beams, respectively. The supervisor system of TrueBeam
linear accelerator communicates with all subnodes of the machine with a frequency
of 100 Hz. Therefore, corrections of the beam can be applied every 10ms. All four
linacs are calibrated that 100 MU correspond to 1Gy in the depth of maximum dose,
a field size of 10x10 cm2 and a source surface distance of 100 cm. Tissue phantom
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ratios (TPR20/10) for the two beams in the different institutions can be found in
Table II. Three linacs (ICO, ICH, KSW) were equipped with a Millennium MLC
and one linac (USZ) with high definition MLC (HDMLC). Both MLCs have in total
60 leaf pairs. For the Millenium MLC, the inner 40 leaf pairs have a width of 0.5
cm and the outer leaf pairs have a width of 1 cm, total length of the MLC is 40 cm.
For HDMLC, the total length is 22 cm, the inner 8 cm are covered by 32 leaf pairs
with a width of 0.25 cm, the outer leaf pairs have a width of 0.5 cm. Data on the
transmission and dynamic leaf gap in the differentinstitutes can be found in Table
5.2.
Table 5.2: Characteristics of the MLCs of the five institutes and tissue phantom
ratio (TPR20/10) for the two beams. At USZ, a HDMLC is installed, which differs
in transmission (T) and dynamic leaf gap (DLG) from the Millenium MLC.
ICH USZ KSW ICO
T X6FFF (%) 1.6 1.0 1.6 1.6
T X10FFF (%) 1.8 1.2 1.7 1.8
DLG X6FFF (mm) 2.0 0.9 1.3 1.1
DLG X10FFF (mm) 2.0 1.0 1.5 1.4
TPR 20/10 X6FFF 0.623 0.631 0.630 0.631
TPR 20/10 X10FFF 0.706 0.702 0.705 0.707
5.3.2 Treatment planning
Treatment planning was always performed with Eclipse®treatment planning system
(Varian, Palo Alto, Medical Systems). RA plans were optimized using progressive
resolution optimizer (PRO) 8.9, for IMRT plans dose volume optimizer (DVO) 8.9
was used. Dose distributions were calculated using anisotropic analytical algorithm
(AAA) 8.9 algorithm with a calculation grid size of 2.5 mm; for targets with a
diameter below 2 cm a calculation grid size of 1.2 mm was used. All treatments
were planned with X10FFF or X6FFF beam. For RA the 1–4 arcs were used for
treatment planning (average 2.12), for IMRT 4–7 field were used (average 5.40). The
maximum dose rate was chosen according to the clinical needs. For small doses per
fraction it is sometimes beneficial to restrict the maximum dose rate to reduce the
dose to healthy tissue. Additionally, since the effect of the high dose rate on healthy
tissue is not yet known, the maximum dose rate was restricted for some cases.
5.3.3 Quality assurance systems
The multicenter study allowed the inclusion of different QA devices for verification
(5.1).
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Gafchromic EBT2 film
GafchromicrEBT2 (ISP, Ashland) film (20.3 x 25.4 cm2) was used in a solid water
phantom (30x30x20 cm3). One to three transversal planes were verified. For each
sheet of film an individual five step calibration was done, by irradiating 5x2.5 cm
pieces of film (using 6 Mv flattened beam) with doses between 0Gy and 1.2 times
the maximum dose. Additionally it was corrected for the light source inhomogeneity
of the flatbed scanner (Epson 10000XL) and the film thickness using B-component
of RGB readout. The films were evaluated using the R readout (up to a dose of 6
Gy) and above that dose the G readout in a home-made gamma analysis software
(MATLAB, MathWorks, USA). Films were scanned with a resolution of 150 dpi,
resulting in a distance between two measurement points of 0.17mm.
DELTA4 phantom
DELTA4r(ScandiDos, Uppsala, Sweden) is a cylindrical phantom for pretreatment
patient QA. Absolute dose is measured in 1069 p-Si diode detectors arranged in two
orthogonal detector arrays. The spacing between detectors is 5mm in the central
part (8x8 cm2 ) and 10mm outside (20x20 cm2). The diameter of the detectors is
1mm. Properties of the phantom have been described in detail by Bedford et al [6].
ARCCHECK
ARCCHECKr(Sun Nuclear Corporation, Melbourne, USA) is a cylindrically shaped
QA device with 1386 diode detectors of a size of 0.8 x 0.8 mm2 helically arranged in
a physical depth of 29 mm and a detector spacing of 10 mm. Both the array diam-
eter and length are 21.0 cm. The inner cavity has a diameter of 15.0 cm. Central
axis dose was simultaneously measured by a Farmer-type chamber (PTW, Freiburg,
Germany) positioned at the center of the cavity by a dedicated insert. The dose
measured by the phantom was the absolute dose, no correction was applied.
MATRIXX
MATRIXXr(IBA, Schwarzenbruck, Germany) is a two dimensional ionization cham-
ber array, consisting of 1024 (32x32) independent parallel plate cylindrical ionization
chambers (diameter 4mm, height: 5.5 mm, sensitive volume: 70 mm3) arranged in a
square of 24x24 cm2. The distance between each ionization chamber is 7.5mm from
center to center of adjacent chambers. This system was calibrated in absolute dose
for each beam energy and used in the same way as for RapidArc with FF fields [129].
The treatment plans were projected on a phantom made up of a CT scan of the MA-
TRIXX with 5 cm of plexiglas above and underneath the active measuring area to
account for build up and backscatter. The GAI was then evaluated comparing the
irradiated and calculated verification plans with the gamma evaluation method im-
plemented in the measuring software OMNIPRO (version 1.5, IBA, Schwarzenbruck,
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Germany).
5.3.4 Gamma analysis and statistics
All plans were evaluated using a global gamma agreement index (GAI). As gamma
criteria 3% dose difference (DD) (from isocenter dose) and up to 3 mm distance
to agreement (DTA) was used, pixels with less than 10% of max dose were not
taken into account. The calculated dose was taken as the reference. Each arc was
evaluated separately and the average was taken. For MATRIXX and gafchromic film
dosimetry, the measured dose was manually adjusted during evaluation. Differences
of mean values were tested on significance using an unpaired Mann-Whitney U-test.
p-values below 0.05 were considered to be significant. A one-way ANOVA was used
to evaluate if any of the variables [beam energy, verification device, max dose rate,
PTV size, number of monitor units (MU)] had a statistically significant effect on
the gamma index.
5.4 Results
Patient specific plan verification was performed for a total of 224 volumes in four dif-
ferent institutes. Average gamma score was 98.9% (+/−1.1) (3 mm, 3%). All four in-
stitutes showed equally good gamma scores (table 5.3). The histogram of GAIs (Fig.
Table 5.3: GAI (in %) of the different institutions. 1 SD is given in brackets.
ICH USZ KSW ICO total
Total 98.7 (1.0) 99.4 (0.8) 99.4 (0.7) 98.0 (1.8) 98.9 (1.1)
RA 98.7 (1.0) 99.4 (0.9) 99.4 (1.1) 98.0 (1.1) 98.8 (1.1)
IMRT — 99.3 (0.9) — — 99.3 (0.9)
X6FFF 98.6 (1.0) 99.3 (0.7) 99.5 (0.5) 98.3 (1.8) 99.1 (1.0)
X10FFF 98.7 (1.0) 99.7 (0.8) 99.3 (0.9) 97.7 (1.8) 98.8 (1.2)
5.1) shows that only three plans had a GAI below 95%. In all the four clinics, a GAI
below 95% means that the plan failed preclinical QA and needs further investigation.
Dose calculation, as well as dose delivery, was equally accurate for IMRT and RA
delivery (IMRT: GAI=99.3% (61.1); RA: GAI=98.8% (61.1)) as well as for the two
beams evaluated (X6FFF: GAI=99.1% (+/−1.0); X10FFF: GAI=98.8% (+/−1.2)).
Four different devices were used for verification. The average GAI for the plans veri-
fied with the high resolution gafchromic films was 99.4% (+/−1.01), which is higher
than for plans verified with the ARCCHECK (GAI=98.8% (+/−1.4%), p<105) and
the MATRIXX (GAI=98.7% (+/−1.4%), p<105) devices. Plans verified with the
DELTA4 phantom showed a GAI=99.4% (+/−0.86) similar to the gafchromic ones.
Figure 5.2 shows that there is no dependency of the GAI on the maximum dose rate
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Figure 5.1: Histogram of GAI for both energies and all four institutions.
used during irradiation of the arc. Similarly no dependence on the mean dose rate
was found. GAI decreased with increasing ratio of MU to dose per fraction (Fig.
5.2) (p<105), which is an indicator for the modulation of the plan. GAI slightly
decreased with decreasing target volume (p<0.02) (Fig. 5.2). For ARCCHECK and
DELTA4 phantom (no manual adjustment of dose distributions) small volumes were
more sensitive to setup errors due to the discrete character of the detectors.
Two institutions (USZ and KSW) additionally performed point dose measurements
in the isocenter using a PinPoint chamber (USZ) and a Farmer chamber (KSW).
Dose differences for a total of 52 patients are shown in Fig. 5.3. Mean dose difference
is 0.34% (significantly different from 0,p<0.01). Both institutions showed a mean
dose difference slightly above 0% (KSW: 0.30%, USZ: 0.38%). In 88% of cases, the
verified isocenter dose was within +/−2% (Fig. 5.3). Larger dose deviations were
mostly due to sharp gradients in the measurement point. Therefore, small setup
errors can have a large impact on the result.
5.5 Discussion
An increasing interest in flattening filter free beams is evident in recent years [53, 38,
67, 65, 66, 39, 39, 20, 126, 124, 123, 99, 118]. An extensive retrospective investiga-
tion on technical and quality assurance data from the treatment of 224 patients from
four radiotherapy departments were performed to provide evidence about intensity
modulated fields using the FFF modality included in the new TrueBeam accelerator.
The analysis of the technical and delivery features of the new linac accelerator True-
Beam was performed in different institutes, with a variety of clinical indications,
and dose prescriptions.Furthermore, the early clinical data of a subsection of these
patients have recently been published [111].
The FFF characteristic to increase the dose rate up to 2400 MU/min (i.e. 24 Gy/min
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Figure 5.2: Dependency of the GAI on A) monitor units, B) target volume. C)
mean dose rate and D) maximum dose rate.
in standard condition) enables a reduction in beam on time, in particular for hy-
pofractionated treatments where the treatment beam on time can be lower than 2
min (if FFF is associated with VMAT technique).
The introduction of a new accelerator with a new method of operating has to be
supported by an extensive dosimetric verification which must include both machine
general performance and verification of treatment plans by measurements of de-
livered dose distributions. Hrbacek et al. [53] reported the data of the clinical
commissioning of the flattening filter free linear accelerator TrueBeam, showing the
capability of delivering RT treatments safely. In this work we have focused on dosi-
metric verifications of modulated plans, performed both as part of commissioning
and as patient specific QA of clinical treatments. To our knowledge, very little data
have been reported on the pretreatment quality assurance in delivering FFF treat-
ments using modulated treatments [118]. The authors believe that a wide patient
specific QA analysis using prior experience and tools is required when implementing
a new technology before reaching the patient. In particular, a comprehensive patient
specific QA protocol based on results from a large number of patients, from multiple
sites, and using different and independent devices should be considered to verify the
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Figure 5.3: Dose differences (%) measured in the isocenter for in total 52 patient.
Mean dose difference is 0.34 % (significant different from 0, p < 0.01).
treatment accuracy. For this reason, one of the first aims of the European TrueBeam
council was the interverification of a cohort of patients for cross-validation. The ob-
jective of this study was to verify whether machines in different institutes and with
different instruments and procedures could give a common results about the quality
of the delivery in basic conditions, that is the reason why no further variables were
added in the analysis (such as inhomogeneous phantoms, etc.).
In this study, different instrumentations were used checking a point, a plan (2D de-
tectors, and film), or the volumetric shape (DELTA4 and ARCCHECK), for some of
these devices, the evaluation of VMAT plans has already been published in literature
[30, 84] but never for FFF beams. Gafchromic, ionization chamber, and diodes were
used. Spatial resolution ranged from 0.2mm for the Gafchromic to 7.5mm for MA-
TRIXX. This different spatial resolution has to be taken in account when deciding
which device to use for QA, in some cases (e.g., very small lesions, or highly modu-
lated dose distributions), a higher resolution is required and a low resolution device
as MATRIXX could not be the optimal choice; the subset of plans considered with
these characteristic is the reason of the lower mean value obtained with MATRIXX
compared with Gafchromic. Nevertheless, the great fraction of low modulated plans
(e.g., SBRT) made the GAI values not so affected by the different resolutions of the
devices used.
The evaluation of calculated dose on Eclipse and delivered dose at TrueBeam mea-
sured by four different devices indicated an excellent agreement for both IMRT and
VMAT. Three plans resulted with a GAI<95%, in one case, it was a two-lesions
single-isocenter plan optimized with four arcs and verified with MATRIXX. The
highly modulated dose distribution achieved, in combination with the discrete spac-
ing of detectors may lead to a low GAI. In case transmission or dynamic leaf gap were
entered slightly incorrect into the TPS, a high modulation could increase leakage
through the MLC leading to a decrease in GAI, some evidence of this correlation is
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present in literature [30, 42]; this can partly be the reason of the difference in uncer-
tainty between two centers using the same device as shown in Table III. The result
can be caused by the sum of dosimetric and mechanical differences (e.g. DLG) that
can exist between both Linacs and MLCs, though of the same model. The other two
plans with a GAI<95% covered very small target volumes (5–6 cm2) that are some-
times prone to dose calculation inaccuracies as shown in Refs. [32, 92, 33]. Better
results could have been obtained with a 1mm calculation grid (and a 1mm DTA)
but the 3mm DTA choice was taken in order to have more homogeneous results
with reference to the resolution range of the QA devices used (up to 7.5 mm for
MATRIXX). Point measurements performed with PinPoint and Farmer chambers
showed mean difference of 0.34% between the ion chamber measurements and the
Eclipse computed doses, results very similar to those found by O’Daniel et al [91].
Measurements were performed for plans of variable complexity: lung stage I and
lung metastases, metahepatic diseases, spinal tumors, pancreatic lesions. Therefore,
considering the large variety and large number of plans (224) verified by means of
systems with different characteristics in terms of geometry and detectors, the high
dose rates achievable (up to 2400 MU/min), and the different dose prescriptions
(from 1.8 Gy/day to 25.0 Gy/day), the obtained results assess the reliability of FFF
delivered doses. Additionally the study presents a set of QA devices suitable for the
use in high dose rate flattening filter free beams; clearly, the device-specific consider-
ations in relation to the different plan characteristics (e.g., high resolution required
for SBRT or very modulated plans) already present in literature, remain valid also
for FFF beams.
5.6 Conclusion
The TrueBeam FFF modality, analyzed with a variety of verification devices and
planned with Eclipse planning system is dosimetrically accurate (within the specified
limits 3 mm/3%) for both X6FFF and X10FFF beam energy.
Chapter 6
Clinical application of flattening
filter free beams for extracranial
stereotactic radiotherapy∗
6.1 Abstract
Purpose: To investigate the clinical application of flattening filter free (FFF) beams
at maximum dose rate for stereotactic body radiotherapy (SBRT).
Methods and Materials: Patients with tumors in the lung or abdomen were
subjected to SBRT using 6 MV FFF or 10 MV FFF beams. For each patient, three
plans were calculated using 6 MV flattened, 6 MV FFF and 10 MV FFF beams.
Treatment times were recorded and analysed, and tumor displacements were assessed
by pre- and post-treatment cone beam computed tomography (CBCT).
Results: Altogether, 26 patients (16 lung, 10 abdominal tumors) were treated. The
average dose rate per patient ranged from 442 to 1860 MU/min. Beam-on time was
on average 1.6 min (1SD = 0.6 min), with the total treatment times recorded at 18.5
min (1SD = 3.5 min). The time advantage of using FFF beams was dose-dependent
and started at 4 Gy for 6 MV FFF and at 10 Gy for 10 MV FFF beams. The
average of the tumor displacements during treatment was 2.0 mm (1SD = 1.0 mm).
Conclusions: SBRT using FFF beams is time efficient and associated with excellent
patient stability. According to Van Herk’s formula, ITV to PTV margins of 6 mm
are sufficient in our patient cohort. Further studies are necessary to assess clinical
outcome and toxicity.
∗This chapter has been published in Radiotherapy and Oncology, Vol. 106, No. 2, February
2013 (Lang et al [72]).
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6.2 Introduction
Photon beams produced by conventional C-arm linear accelerators are directed
through a flattening filter, resulting in uniform photon fluence. Novel linear ac-
celerator technology allows compensation of nonuniform photon fluence by the use
of modulated treatment techniques. Several recent planning studies demonstrated
that dose distributions achieved with flattening filter free (FFF) beams are at least
similar to those with flattened beams [139, 95, 106, 118, 124, 123]. When the filter
is removed from the photon beam, the dose rate can be multiplied, thereby sub-
stantially shortening beam-on time, which makes FFF beams especially attractive
for stereotactic radiotherapy with high dose per fraction. This appears important
because it has beenestablished that a reduction in treatment time translates into
improved patient stability and treatment accuracy [103, 51]. The use of volumetric
modulated arc radiotherapy (VMAT) for stereotactic body radiotherapy (SBRT)
has recently been shown to shorten beam on times by a factor of 3.1 if compared to
static field IMRT (VMAT: 3.9 min, IMRT: 12 min) [94]. Further reductions in beam
on time may be achieved by using FFF beams in conjunction with VMAT. How-
ever, a potential time advantage depends on dose per fraction and is co-determined
by modulation complexity, tumor location and mechanical aspects of treatment de-
livery, such as gantry speed and MLC speed. We present our experience with the
clinical application of FFF beams for (SBRT). We analysed our first 26 patients
treated with this technique, focusing on the time advantage using FFF beams ver-
sus flattened beams, and patient stability.
6.3 Materials and Methods
Patients with primary or metastatic tumors of the lung or upper abdomen were sub-
jected to SBRT using the TrueBeam® linear accelerator (Varian Medical Systems,
Palo Alto, CA). Treatment planning was performed on the average projection of
4-dimensional computed tomographies (4DCTs) in the Eclipse® treatment plan-
ning system (Varian Medical system, PRO 8.9, AAA 8.9) using 6MV (X6FFF) or
10MV (X10FFF) FFF beams. Hrbacek et al. have previously reported a detailed
description of the beam characteristics [53]. All patients were planned using VMAT
(RapidArc®, Varian Medical Systems) technique with 1-3 arcs allowing the op-
timizer to use the maximum dose rate of 1400 monitor units/min (MU/min) for
X6FFF and 2400 MU/min for X10FFF beams. Tumors of the lung were planned
with X6FFF beams and tumors of the upper abdomen with X6FFF or X10FFF
beams (depending on tumour depth within the patient). In the case of lung tumors,
avoidance sectors or partial arcs were used to spare the contra-lateral lung. Plan-
ning objectives were chosen according to current RTOG protocols (see RTOG 0915
protocol). Treatment plans were normalized to the maximum dose and the dose
was prescribed to the 60%-90% isodose line that covered 95% of the volume. The
conformity index (CI, volume enclosed by the prescription isodose / PTV volume),
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as well as the number of MU and mean dose rate, were recorded. Each plan was
verified prior to patient treatment on the Delta4r-phantom (ScandiDos, Uppsala,
Sweden). The passing criteria for the verification measurement was a gamma agree-
ment index (GAI) of 95% (DD = 3%, DTA =2 mm) To ensure positional stability,
reproducibility of the set-up and patient comfort, patients were placed supine in a
customized vacuum bag (CIVCO, Kalona, IA). An abdominal compression device
was used in selected patients for tumors close to the diaphragm. For management
of tumor motion, an internal target volume (ITV) was contoured on the 4DCT im-
ages including all tumor positions within the breathing cycle. Image guidance was
performed by pre treatment cone beam computed tomography (CBCT). In the case
of lung tumors, an automated ITV match was performed. For abdominal lesions,
an automated match to surgical clips (1 patient) or a manual match to anatomical
structures (all other patients) was performed. Every match was checked by the re-
sponsible clinician. Patient stability during treatment was observed by monitoring
the patients’ breathing amplitude using an RPM gating system (Varian Medical Sys-
tems, Palo Alto, CA). Treatment was only delivered if the breathing amplitude and
frequency agreed within +/- 20% of the values acquired on the 4DCT. If amplitude
or frequency were out of tolerance, an individualized training was undertaken with
the patient. Beam-on time, as well as total treatment time, was measured each day
for all the patients and for each patient the mean values and standard deviation
(SD) was calculated. In order to evaluate the time efficiency benefit using FFF
beams, three plans were calculated using 6 MV flattened (X6), X6FFF and X10FFF
beams for each patient. Beam-on times for the three plans were measured using
a stopwatch and subsequently compared.Shortened beam-on time should translate
into minimal intra-fraction patient and target shifts. Therefore patient shifts were
determined by comparing the bony match of pre- and post-treatment CBCTs and
baseline shifts were assessed by comparing the position of the tumor in pre- and
post-treatment CBCTs in relation to the bony anatomy. Total tumor displacement
includes patient shift as well as baseline shift. For estimation of ITV to PTV mar-
gins, Van Herk’s formula was used [122]: Systematic Σ and random σ errors were
calculated for intra-fractional motion. A systematic contouring error of 2 mm was
assumed [116]. Setup error was neglected. ITV to PTV margins M were calculated
using Van Herks formula adapted for lung tissue [14]:
M = 2.5Σ + β
√
σ2 + σ2P − βσp (6.1)
where β = 0.84 and σP = 6.4mm
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6.4 Results
6.4.1 Tumors and volumes treated
Between July 2010 and November 2011, 26 patients were treated - 16 patients with
tumors in the lung and 10 patients with tumors in the abdomen (4 liver, 4 pancreas,
2 adrenal gland tumors). The median age of the patients was 64.5 (46-89) years. In
2 patients, 2 PTVs were treated, respectively. Of the 28 lesions treated, 16 lesions
were treated with curative intention (11 lung, 4 pancreas, 1 liver), and 12 lesions
were metastases (6 lung, 2 adrenal gland, 4 liver). In 2 patients, lung metastases
were treated in the remaining lung after previous pneumonectomy (P1 and P14, see
Table 6.1). The mean PTV size was 49.7 cm3 (9.8 - 283.5 cm3).
6.4.2 Treatment planning and treatment delivery
Mean dose rates of the treatments varied between 442 MU/min and 1394 MU/min for
X6FFF and between 1076 MU/min and 1860 MU/min for X10FFF beams, mainly
depending on the dose per fraction and the number of arcs used. Individualized
radiation doses and fractionation schedules were used (Table 6.1). The mean GAI
for pre-treatment QA was 98.97% (1SD = 0.82%), showing that the FFF beams
were delivered correctly (Table 6.1). All plans fulfilled the planning objectives, and
most plans achieved a CI close to 1. Only one plan with the tumor close to the chest
wall showed a larger CI of 1.47.
6.4.3 Treatment and beam-on time
Treatment times for all patients were recorded to investigate time efficiency of using
FFF beams. Patient setup in the room required on average 6.5 min (1SD = 4.6
Figure 6.1: Total treatment time, separated into patient setup inside the room,
CBCT acquisition, matching of the CBCT and actual beam on time.
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Table 6.1: Patient and Treatment Details: Conformity index (CI) is defined as the volume enclosed by the prescription
isodose divided by the PTV volume. Delta4 phantom was used to measure gamma agreement index (GAI, 2mm/ 3%).
patients site PTV schedule energy # arcs # MU mean DR max DR mean T (treatment) mean T (total) GAI CI
(ccm) MeV (MU/min) (MU/min) (min) (min) (%)
P1 lung 15.6 8 x 4.5 Gy @70% X6FFF 2 1074 851 1200 1.26 18.2 (+/- 4.4) 99.3 1.06
P2 lung 37.7 10 x 5 Gy @80% X6FFF 1 1563 1351 1400 1.16 26.8 (+/- 7.1) 97.3 1.21
P3 lung 14.7 5 x 8.5 Gy @85% X6FFF 2 2530 1225 1400 2.06 18.1 (+/- 4.8) 98.8 1.19
P4, V1 lung 37.5 3 x 10 Gy @84% X6FFF 2 3018 1372 1400 2.2 15.5 (+/- 3.9) 98.7 1.07
P4, V2 lung 37.7 3 x 10 Gy @84% X6FFF 2 2309 1346 1400 1.72 12.2 (+/-2.1) 98.6 1.07
P5 lung 9.8 4 x 10 Gy @89% X6FFF 2 3074 1389 1400 2.22 19.6 (+/- 3.4) 99.4 1.16
P6 lung 64 10 x 6 Gy @85% X6FFF 3 1129 912 1400 1.24 19.2 (+/-3.2) 99.6 1.14
P7 lung 18.7 15 x 3.3 Gy @85% X6FFF 2 902 442 600 2.04 15.5 (+/- 3.9) 99.6 1.23
P8, V1 lung 14.1 12 x 4 Gy @79% X6FFF 2 1079 941 1400 1.14 21.0 (+/- 8.4) 97.4 1.47
P8, V2 lung 5.9 11 x 4 Gy @87% X6FFF 2 1116 904 1400 1.24 19.3 (+/- 3.2) 97.5 1.09
P9 liver 36.3 10 x 5 Gy @85% X6FFF 2 956 592 600 1.62 18.1 (+/- 3.9) 100 1.11
P10 liver 283.5 10 x 4 Gy @80% X6FFF 2 1114 801 1000 1.41 26.5 (+/-3.3) 99.1 1.21
P11 pancreas 131.8 2 x 6 Gy @78% X6FFF 1 1258 1224 1400 2.06 23.2 (+/- 2.9) 99.1 0.98
P12 pancreas 24 10 x 5 Gy @87% X6FFF 1 1079 1372 1400 0.79 25.8 (+/- 4.3) 100 1.31
P13 lung 27.4 8 x 7.5 Gy @73% X6FFF 2 1704 830 1400 2.06 13.8 (+/- 3.2) 100 1.05
P14 lung 32.7 12 x 4 Gy @72% X6FFF 2 1082 545 1400 2.02 15.0 (+/- 3.0) 99.1 1.04
P15 lung 24.4 4 x 12 Gy @71% X6FFF 3 4017 1376 1400 2.89 16.1 (+/- 2.8) 99.8 1
P16 liver 42.9 4 x 10 Gy @75% X6FFF 2 2139 1374 1400 1.55 18.7 (+/- 5.7) 98.4 0.97
P17 lung 53.8 4 x 10 Gy @85% X6FFF 2 2263 1355 1400 1.66 17.6 (+/- 3.6) 100 1.04
P18 pancreas 40.9 2 x 6 Gy @76% X6FFF 2 1760 1056 1400 2.04 18.3 (+/- 4.0) 98.9 1
P19 pancreas 30.2 2 x 6 Gy @75% X10FFF 2 1851 1842 2400 1.05 17.9 (+/- 1.2) 97.8 0.99
P20 liver 131.8 4 x 12 Gy @80% X6FFF 2 3860 1396 1400 2.78 15.3 (+/-3.3) 99.5 0.98
P21 lung 19.6 4 x 12 Gy @79% X6FFF 4 3974 1302 1400 3.01 14.0 (+/- 2.1) 99.4 1.02
P22 adrenal 53.5 3 x 10 Gy @78% X10FFF 2 3813 1860 2400 2.03 22.5 (+/-5.1) 98.9 1.01
P23 Lung 22.6 4 x 12 Gy @84% X6 FFF 2 5668 1396 1400 3.36 13.5 (+/- 2.7) 97.9 1.2
P24 adrenal 77.9 4 x 10 Gy @88% X6 FFF 2 3172 1198 1200 2.65 19.7 (+/- 4.1) 99.6 1.02
P25 lung 40.7 10 x 5 Gy @79% X6FFF 2 1364 993 1400 1.38 16.2 (+/- 3.9) 99.2 1.06
P26 lung 61.7 5 x 7.5 Gy @78% X10FFF 2 2170 1076 2400 2.02 18.0 (+/- 2.4) 98.3 1.02
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min). CBCT acquisition required 1.8 min (1SD = 0.5 min) and 6.0 min (1SD =2.8
min) were needed for the tumor match for lung patients, and 9.6 min (1SD = 3.2
min) for abdominal patients (Figure 6.1). Treatment beam-on time was on average
1.6 min (1SD = 0.6 min) with the total treatment times recorded at 17.2 min (1SD
= 3.4 min) and 20.6 min (1SD = 3.7 min) in patients with tumors of the lung
and upper abdomen, respectively (Table 6.1 and Figure 6.1). Figure 6.2 shows the
Figure 6.2: Dependency of the difference in delivery time on the dose (left) and on
the monitor units (right) using X6 beam compared to X6FFF beam (grey triangle)
and using X6FFF compared to X10FFF (black circles). X6FFF saves time if more
than 1000 MU are needed to deliver the plan or if a dose larger than 4 Gy is given.
X10FFF saves time compared to X6FFF if more than 2000 MU are needed or the
dose is larger than 10 Gy.
differences in beam-on time using the X6FFF beam compared to a X6 beam, as well
the difference between X10FFF and X6FFF. From a dose of approximately 4 Gy or
1000 MU, the X6FFF beam allows more rapid treatment delivery compared to the
X6 beam. The time advantage increases with increasing number of monitor units
(R2 = 0.88, p < 0.01) and increasing dose (R2 = 0.80, p < 0.01). The use of the
X10FFF beams has advantages for doses above 10 Gy (p=0.03) or monitor units
above 2000 MUs compared to X6FFF beams (p < 0.01). There was no significant
dependency of time advantage using X6FFF or X10FFF beam on the size of the
treated volume (R2 = 0.01, p = 0.85).
6.4.4 Intra-fractional stability
The average 3D vector of the patient and baseline (tumor in respect to the bones)
shifts during treatment were 2.0 mm (1SD = 0.8) and 1.9 mm (1SD = 0.5 mm),
the total tumor displacement was 2.0 mm (1SD = 1.0 mm) in all patients and
2.1 mm (1SD = 1.2 mm) in patients with lung tumors. Figure 6.3 shows patient
and baseline shifts for lung and abdominal treatments. Intra-fractional motion was
similar for lung and abdomen patients. The maximal shift observed was 5.2 mm.
Shifts in lateral and longitudinal direction were non-systematic, whereas there was
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a slight systematic drift in vertical direction (mean shift 0.54 mm, p < 0.01), due to
sagging and relaxing of the patient in the vacuum bag (Figure 6.3). For stereotactic
Figure 6.3: Patient (bony anatomy) and baseline (tumor in respect to the bones)
shifts for lung and abdominal treatments. Intra-fractional motion was similar for
patients with lung and abdominal tumors. The maximal shift observed was 4.2 mm.
Shifts in lateral and longitudinal direction were non systematic whereas there was a
slight systematic drift in vertical direction (mean shift 0.43 mm, p < 0.01), due to
sagging and relaxing of the patient in the vacuum bag.
radiotherapy with large single fractions, minimal ITV to PTV margins are generally
used. Derived from our calculated random and systematic errors (compare table 6.2
and 6.3) according to Van Herk’s formula, ITV to PTV margins of 6 mm should
be used if the described technique is applied. No dependency of the shifts on the
beam-on time was found (R2 = 0.09, p = 0.78).
6.5 Discussion
Here we reported our experience with the clinical application of stereotactic VMAT
using X6FFF or X10 FFF beams at maximum dose rate. We showed that FFF
beams at maximum dose rate substantially shorten beam-on time; in addition, we
found minimal patient and target shift during treatment.
In our series, most patients had metastasized cancers and were heavily pretreated
with surgery and chemotherapy. Accordingly, the doses prescribed in Gray represent
an individualized treatment approach dependent on the individual patient situation
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Table 6.2: Group mean (GM), systematic Σ and random σ errors for baseline (tumor
in respect to bones), patient (bony anatomy) and tumor (total= baseline + patient)
shifts. Margins M1 (only intrafractional motion) and M2 (intra-fractional motion +
2 mm contouring) for lung tumors calculated according to Van Herks formula.
lung GM (mm) S (mm) s (mm) M1 (mm) M2 (mm)
b
o
n
e
vrt -0.54 0.6 1.18
lng -0.77 0.91 0.51
lat 0.05 0.62 0.58
b
a
se
li
n
e vrt -0.4 0.67 0.37
lng -0.35 0.53 0.46
lat -0.43 0.77 0.59
tu
m
o
r vrt -0.94 0.99 1.08 3.23 6.33
lng -1.12 0.98 0.66 2.74 5.86
lat -0.38 0.54 0.81 1.77 5.6
Table 6.3: Group mean (GM), systematic Σ and random σ errors for baseline (tumor
in respect to bones), patient (bony anatomy) and tumor (total= baseline + patient)
shifts. Margins M1 (only intrafractional motion) and M2 (intra-fractional motion +
2 mm contouring) for abdominal tumors calculated according to Van Herks formula.
abdomen GM (mm) S (mm) s (mm) M1 (mm) M2 (mm)
b
o
n
e
vrt 0.02 0.31 0.42
lng -1.02 0.79 0.34
lat -0.28 0.59 0.38
b
a
se
li
n
e vrt -0.06 0.26 0.64
lng 0.25 0.54 0.35
lat 0.32 0.57 0.71
tu
m
o
r vrt -0.04 0.29 0.93 1.3 5.62
lng -0.77 0.48 0.47 1.34 5.28
lat 0.03 0.45 0.45 1.27 5.26
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and the tolerance of the remaining surrounding organ. In patients with high morbid-
ity, treatment efficiency is important because these patients are not able to endure
long treatment sessions.
We demonstrated that the X6FFF beam provided a time efficient treatment and
was therefore a good choice for our patient cohort. X10FFF had a small additional
benefit for patients receiving more than 10 Gy. However, the use of the higher dose
rate of the X10FFF beam below 10 Gy does not translate into a time advantage due
to the limited speed of the gantry (1 min/arc) [139]. A recent treatment planning
study from our department indicates that X6FFF beams give superior plans for
SBRT of lung tumors, compared to X6 and X10FFF. Therefore, our departmental
policy is to treat lung volumes with X6FFF beams. We did not find a correlation
between the time advantage of using FFF beams and the size of the treated volume.
However, most of the patients had a PTV of similar size and only three patients
had a volume larger than 100 ccm. The inclusion of more patients with larger vol-
umes may change the result. As discussed in [139], the integral dose of FFF beams
decreases with increasing volume and therefore it is expected that from a field size
above 100 ccm, the number of MUs for FFF beams increases and the time advantage
decreases.
The devices used for patient stabilization and the time of treatment delivery are
thought to influence treatment accuracy. Using a stereotactic body frame (SBF)
for immobilization of patients treated with SBRT, the 3D vectors of patient shift
analyzed by pre and post treatment CBCT was 2.1 mm [45] and tumor drift was
2.3 mm (+/- 1.6 mm) [16] or, in a similar study, 5.2 mm (maximum 14.9 mm) [45].
The latter studies did not correlate stability with treatment time. Hoogeman et al.
immobilized patients with vacuum bags and demonstrated significant patient shifts
if the time span between measurements exceeded 15 minutes [51]. The importance
of treatment time for patient stability was shown by a clinical study of patients
with lung tumors treated with SBRT in which the mean patient shift was 5.3 mm if
treatment lasted longer than 34 min, and only 2.2 mm if treatment time was shorter
than 34 min [103]. In a recently published study Dahele et al. analyzed stability
of the patient spine before and after RapidArc SBRT. Mean treatment time was
4.2 min and spine shifts were in the submm range [21]. However spine shift alone
might not reflect bony shift of the whole thorax or, for example, of the sternum,
when the patient relaxes. In our study, the mean beam on time was 1.6 min, the pa-
tient shift was within the submillimeter range and the 3D vector of the total tumor
displacement was 2.0 mm, if all patients were considered, and 2.1 mm for tumors
in the lung. These values represent an excellent level of patient stability for this
technique, which can be at least in part attributed to the shortened beam-on times
due to the use of FFF beams and volumetric arc treatment delivery. We did not find
a dependency of the beam-on time on the stability of the patient. This is mainly
due to the small range of beam on times between 0.84 min to 3.5 min. The high
level of patient stability supports the use of small ITV to PTV margins (in our case
6 mm), which further benefit the patient by potentially reducing toxicity.
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Of clinical concern is a potential increase in toxicity when using FFF beams with
unprecedented high dose rates for the treatment of patients [79, 117]. However,
FFF beams are increasingly used and first clinical studies in patients treated with
SBRT did not result in unexpected toxicity [111]. Furthermore, as SBRT treatment
volumes are small and toxicity is usually mild, it seems unlikely that toxicity will be
significantly increased by using FFF beams for SBRT. In summary, our early clinical
experience indicates that the use of FFF beams at high dose rate for extracranial
stereotactic radiotherapy of patients with tumors in the lung, or abdomen, is very
efficient. The X6FFF beam is generally a good choice for high dose per fraction,
whereas there is only an additional benefit for the X10FFF beam (compared to the
X6FFF beam) at doses above 10 Gy per fraction.
Chapter 7
Development and evaluation of a
prototype tracking system using
the treatment couch ∗
7.1 Abstract
Objective: Tumor motion increases safety margins around the clinical target vol-
ume and leads to an increased dose to the surrounding healthy tissue. We have
developed and evaluated a treatment couch tracking system to counter steer respi-
ratory tumor motion. Three different motion detection sensors with different lag
times were evaluated.
Materials and Methods: The couch tracking system consists of a motion de-
tection sensor, which can be the topometrical system Topos, the respiratory gating
system RPM or the laser triangulation system and the Protura treatment couch. The
control system was implemented in the block diagram environment Simulink. To
achieve real time performance the Simulink models were executed on a real time en-
gine, provided by Real-Time Windows Target. To achieve high control performance
with good reference tracking and good disturbance rejection, a proportional-integral
control system was implemented. The lag time of the couch tracking system using
the three different motion detection sensors was determined with a step function of
2 cm on the position reference signal.
The geometrical accuracy of the system was evaluated by measuring the mean ab-
solute deviation from the reference (static position) during motion tracking. A
hexapod system was moving according to 7 respiration patterns previously acquired
with the RPM system as well as according to a sin6 function with two different
frequencies (0.33 Hz and 0.17 Hz) and the treatment table compensated the motion.
Results: A prototype system for treatment couch tracking of respiratory motion
was successfully developed. We found that short delay times are needed to be able
∗This chapter has been submitted for publication in Medical Physics (Lang et al ).
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to track all respiration frequencies. The laser based tracking system with a small lag
time of 60 ms could track all respiration patterns. An increase in delay time from 60
ms to 130 ms (RPM based system) resulted in a poor tracking performance for the
sin6 pattern (frequency 0.33 Hz). The Topos based tracking system with the largest
lag time of 300 ms was only able to track four respiration patterns. For the four
patient respiration patterns, which could be tracked by all three systems, a mean
absolute deviation of 0.19 mm was achieved using the laser sensor, 0.45 mm using
the RPM system and 0.52 mm using the TOPOS system.
Conclusion: Couch tracking with the Protura treatment couch is achievable. To
reliably track all possible respiration patterns without prediction filters a short lag
time below 100 ms is needed. More scientific work is necessary to extend our proto-
type to tracking of internal motion.
7.2 Introduction
Modern accelerators achieve sub-millimeter accuracy. However, not all tumors are
stable during the treatment session. Tumors in the lung can move up to 16 mm
[114], in the liver up to 34 mm [110] and the thoracic wall moves up to 14 mm [105]
due to respiratory motion. In these cases tumor motion management is needed to
accurately irradiate the tumor while sparing healthy tissue. This becomes impor-
tant for large treatment volumes, where dose to the surounding tissue is a limiting
factor and for hypofractionation, where high doses are applied in a small number of
treatment fractions.
The three motion management techniques currently used in the clinical setting are
motion encompassing treatment, gating and tracking. In comparison to motion en-
compassing treatment, gating allows treatment to a smaller volume; however, at the
cost of substantially increased treatment time. The most sophisticated treatment
technique appears to be tracking because it confines the high dose to the tumor
(small volume) and is time efficient.
Tracking can be achieved by tracing the target volume dynamically with the ra-
diation beam. This was first implemented in a robotic radiosurgery system, the
CyberKnife system [2], and has been further realized by the use of a dynamic multi
leaf collimator (MLC) [89] and the gimbaled head of the VERO system (BrainLab,
Germany) [25]. Another possibility is to leave the treatment beam undisturbed but
to move the treatment couch to achieve a stable tumor position. Several visibility
studies have been performed showing the capability of different couch systems to
perform tracking. In 2005 D’Souza et al [27] presented a couch tracking system
based on a hexapod, which could perform tracking for slow respiration periods of
16s. More recently Buzurovic et al [18], Haas et al [46] and Wilbert et al [135]
have developed more advanced couch control systems using proportional integral
derivative feedback systems. However, none of these couch tracking systems is used
in clinical routine. More research is needed to define optimal tracking settings and
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demonstrate the clinical benefit of couch tracking. We’ve developed a prototype sys-
tem for one-dimensional treatment couch tracking which works with the clinically
available Protura treatment couch and is integrated into a clinical linear accelerator.
To our knowledge the capability of couch tracking for this system has not yet been
shown. Geometric as well as dosimetric accuracy was analysed using three different
motion detection systems with different delay times. This enabled us to show the
effect of different delay times on the tracking performance, which to our knowledge
has not yet been evaluated.
7.3 Materials and Methods
Figure 7.1 shows the components of the tracking system. A phantom which moved in
the vertical direction was imaged and tracked. The system consisted of a motion de-
tection sensor, which could be the topometrical system Topos (CyberTechnologies),
the respiratory gating system RPM (Varian Medical Systems) or the laser trian-
gulation system (MicroEpsilon) and the treatment couch Protura (Civco Medical
Systems).
Protura
Phantom
G
TOPOS System
Gating Camera
Laser triangulation
Topos sensor 1
Topos sensor 2
Laser sensor
Protura
Phantom
Gating block
Figure 7.1: Components of the couch tracking system: A phantom performs a one-
dimensional respiration pattern. The respiration is detected by the RPM gating
system, the TOPOS system or the laser sensor. The Protura treatment couch com-
pensates the breathing motion.
7.3.1 Motion detection sensors
Three different position detection sensors were integrated into the control system
for the treatment couch tracking.
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Topometrical Surface detection
A prototype of the topometrical surface detections system Topos (Cyber Technolo-
gies, Ingolstaft, Germany) previously described by Lindl et al [76] was used for the
acquisition of the respiratory signal. It was composed of two beamers which pro-
jected structered white light onto the patient and two cameras, which acquired the
images under a certain observation angle (Figure 7.2). It used phase measuring
triangulation. The surface was calculated on the Topos server and the information
was passed on to the Topos client via TCP/IP. The Topos client calculated the res-
piration signal and transmitted it to Matlab (MathWorks, Massachusetts, USA) via
a .net named pipe.
Topos imaged the motion of the patient surface within a volume of 40x50x50 cm3.
Windows Computer
Figure 7.2: Schematic drawing of a couch tracking system
For the acquisition of the respiratory motion a volume of 5x5x5 cm3 was defined
and the motion of the surface in this volume was tracked. The three dimensional
vector of the respiratory motion was written to a named pipe. The measuring rate
of the system was 10 Hz, the delay time was approximated by Lindl et al to be 250
ms [76]. The accuracy in vertical direction was below 0.5 mm [76].
Single Point Infrared detection
The commercially available respiratory gating system RPM (Varian Medical Sys-
tems, Paolo Alto, USA) was used in a non-clinical mode. A 6-point marker block
was detected in three dimensions using an infrared camera system (gating camera).
The non-clinical mode allowed the transmission of the marker blocks’s three dimen-
sional position to the serial port of the RPM workstation. This signal could be
further used for couch tracking (Figure 7.2). The measuring rate of the system was
25 Hz.
Laser triangulation measurement
The third position detection sensors used, was the laser triangulation displacement
sensor opto NCDT 1302-100 (Micro Epsilon, Brownland, USA). The semiconductor
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laser had a wavelength of 630 nm and a power less than 1 Watt. It had a one
dimensional measurement range of 100 mm and was installed 100 mm above the
surface of the respiratory phantom. The measuring rate of the system was 750 Hz
and it had a resolution of 50 um.
7.3.2 Treatment couch
Treatment couch tracking was performed using the 6 degree of freedom (DoF) couch
Protura (Civco Medical Systems, Iowa, USA)). The system used for our investi-
gation is installed on a Trilogy linear accelerator (Varian Medical Systems, Paolo
Alto, USA) used for clinical routine. The controller of the couch could be addressed
using a dynamic link library (dll). The only difference between research mode and
clinical mode was a modified firmware for the research mode to reduce delay times.
In research mode, sending of commands via the dll took 0.9 ms. The request of
information from the controller took 21.8 ms. The maximum allowed speed of the
couch was 16 mm/s. The Protura couch is able to track in 6DoF, however at the
moment the system was implemented for 1DoF tracking (vertical).
7.3.3 Control system
The controller was implemented in the block diagram environment Simulink (Math-
Works, Massachusetts, USA). To achieve a high control performance with good
reference tracking and good disturbance rejection, a proportional-integral controller
according to the following equation was implemented:
z(t) = kp · u(t) + ki · (u(t)− u(t− 1)) (7.1)
z(t) is the controller output in vertical direction at the discrete time t, u(t) is the con-
troller input, kp is the proportional gain and ki the integral gain. The proportional
and integral gain were determined using Ziegler and Nichols tuning rules. To ensure
that the tracking system worked in real time conditions, the Simulink models were
executed on a real time engine, provided by Real-Time Windows target. Different
filter designs for the three motion detection sensors were implemented to smooth the
measured input signal. For the Topos based and the RPM based tracking system
a finite impuls response (FIR) filter was used, for the laser based system a infinite
impulse response (IIR) filter was implemented.
7.3.4 Evaluation of the tracking accuracy
The lag time of the couch tracking system using the three different imaging systems
was determined using a step function of 2 cm. The time between the initiation of
the step and the reaction of the imaging system was measured. The geometrical ac-
curacy of the system was evaluated by measuring the residual signal, when tracking
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was active. A hexapod system (Physics Instruments, Germany) was moved accord-
ing to a sin6 function with two different frequencies (0.33 Hz and 0.17 Hz) and the
treatment table compensated for the motion. The sin6 function to simulate breath-
ing was chosen based on the work of Lujan et al [80]. Additionally, the hexapod
system was moving according to 7 different respiration patterns of patients previ-
ously acquired with the RPM system during 4 dimensional computer tomography
(4DCT). Mean frequency and amplitude of these patterns are summarized in table
7.1. The geometrical accuracy of the system was evaluated by measuring the mean
Table 7.1: Characteristics of respiratory pattern of seven patients: Respiration pe-
riod T with standard deviation (SD), respiration peak to peak amplitude A with SD
and the baseline drift of the patient due to relaxation normalized to 100 s.
pattern T (s) SD(T) (s) A (mm) SD(A) (mm) drift (mm/100s)
1 8.69 0.84 10.21 0.76 6.9
2 8.32 0.75 10.65 1.21 7.6
3 6.79 1.59 10.38 4.03 0.7
4 6.06 0.53 4.91 0.87 1.3
5 5.56 1.38 5.34 1.13 0.8
6 5.51 1.41 0.35 0.94 0.9
7 3.49 0.28 5.33 0.75 2.6
sin6 1 6.00 0.00 10.00 0.00 0.0
sin6 1 3.00 0.00 10.00 0.00 0.0
absolute deviation from the reference position (static position), when tracking was
applied. We considered the tracking as successful if the deviation was reduced by a
factor of two between no tracking and tracking applied. The factor of 2 was chosen
because if the reduction was less then 2 the system was likely to oscillate due to the
breathing with a higher frequency than the breathing frequency. This we considered
as disturbing for the patient.
Additionally the dosimetric effect of using tracking to compensate respiration com-
pared to no tracking applied was investigated. Gafchromic films were irradiated
for 60 s with and without tracking of one respiration pattern (pattern 4, using the
laser based tracking system) with an open 2x2 cm2 field at gantry angle of 90°. The
broadening of the penumbra compared to static fields was evaluated.
7.4 Results
7.4.1 Lag times of the different systems
Figure 7.3 shows the response on a step function (20 mm) of the tracking system
with the three different motion detection sensors. The laser system worked with a
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high sampling rate of 750 Hz and has according to the manufacturer a lag time of
below 1 ms. From the response on the step function a lag time of 57 ms of the total
system (laser position acquisition and couch tracking) could be derived. Therefore
the lag time of the Protura couch was approximately 56 ms. The lag time of the
RPM system was 74 ms and of the TOPOS 244 ms. The total lag time of the
Protura couch combined with the RPM system was 130 ms and combined with the
TOPOS system 300 ms.
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Figure 7.3: Response of the couch tracking system on a step function. The delay
was different for the three different image acquisition systems.
7.4.2 Geometric and dosimetric accuracy
Figure 7.4 shows three different respiration patterns and the residual motion when
tracking was applied. All three patterns could be tracked reliably if the laser based
tracking approach was used for distance measurements. Pattern 3 (bottom) could
not be tracked reliably (reduction in mean absolute deviation of less then a factor
of two), when the Topos sensor was used. If the RPM sensor was used, the residual
mean absolute deviation was reduced by a factor of 2.8 compared to a reduction of
10.56 if the laser sensor was used. Patterns 1 and 4 could be tracked by all three
systems. Table 7.2 summarizes the residual motion for all seven respiration patterns.
The laser based tracking system and the RPM based system could track all seven
respiration patterns, the Topos based system was only able to track 4 out of the 7
patterns. Similarly, the tracking system based on the laser sensor could track both
frequencies (0.33 Hz and 0.17 Hz) of the sin6 function and the tracking system based
on the RPM sensor and the TOPOS sensor could only track the slower frequency.
Patient motion leads to broadening of the penumbra and an underdosage at the
field edges (Figure 7.5 and Figure 7.6). Tracking can correct for this motion and the
associated broadening of the penumbra. The increase in the penumbra of the profile
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Figure 7.4: Respiration signal and residual signals, if tracking is applied using the
three different motion detection sensors. top: Pattern 4, middle: Pattern 1, bottom:
Pattern 3
for a motion of 6 mm was 1.4 mm. With tracking applied there was no increase in
the penumbra (Figure 7.6)
7.5 Discussion and Conclusion
A one dimensional treatment couch tracking system, which could compensate for
respiratory motion of the patient, was developed and evaluated. The respiratory
motion was detected by three different surface detection systems with different de-
lay times. We found that short delay times are needed to be able to track all the
respiration frequencies. The laser based tracking system with a small lag time of
approximatly 60 ms could track all the respiration patterns. An increase in delay
time from 60 ms to 130 ms resulted in an inadequate tracking performance for the
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Table 7.2: Mean deviation from the baseline without tracking applied and with the
three different tracking systems. If tracking was not possible it is marked with NP.
Pattern mean deviation (mm)
No tracking Laser sensor RPM Topos
1 3.93 0.20 0.54 0.65
2 3.94 0.21 0.50 0.51
3 3.87 0.37 1.38 NP
4 1.84 0.17 0.45 0.47
5 2.09 0.23 0.65 NP
6 1.68 0.17 0.35 0.44
7 1.65 0.51 0.77 NP
sin6 1 3.70 0.21 0.43 0.97
sin6 2 3.70 0.47 NP NP
Figure 7.5: Comparison of an open field, radiated on a gafchromic film in a mov-
ing phantom (middle), on a static phantom (left) and on a moving phantom with
tracking applied (right).
sin6 pattern (frequency 0.33 Hz). The system with the largest lag time of 300 ms
was only able to track 4 of the breathing patterns. Prediction filters might be an
option to improve the accuracy of the this system. Buzurovic et al [17] and Qiu et al
[104] have shown that prediction filters improve the tracking accuracy for lag times
between 125 ms - 250 ms.
For the four patient respiration patterns, which could be tracked by all three sys-
tems, a mean absolute deviation of 0.19 mm was achieved using the laser sensor, 0.45
mm using the RPM system and 0.52 mm using the TOPOS system. For all seven
patient patterns tested, a mean absolute deviation of 0.27 mm was achieved using
the laser sensor and of 0.65 mm using the RPM system. Similarly, Buzurovic et al
[18] showed an accuracy of 0.18 mm for an experimental couch in combination with
the Align RT system (VisionRT, London, UK). The results are difficult to compare
because different respiration patterns were used, but are non the less in the same
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Figure 7.6: Profiles of an open field (2x2 cm2) along the direction of respiration
motion, acquired with gafchromic films. Black: static phantom, no motion, blue:
phantom in motion, no tracking, red: phantom in motion, tracking
order of magnitude. Lee et al [74] found a root mean square error of 2.34 mm for
their experimental couch in combination with Align RT. The larger error probably
results due to their large lag time of 251 ms.
One limiting performance factor of our system was the speed of the couch. We were
limited to a velocity of 16 mm/s. For respiratory pattern 3 it was not possible to
follow the fast respiratory motion of the patient with this velocity. Souza et al [27]
had a similar problem, their experimental couch system could not track breathing
cycle times of 4s due to the limited speed of the treatment couch. Buzurovic et
al [19] used an Elekta Precise Tablewith a maximum speed of 50 mm/s and did
not experience any limitations with this velocity. However, patient tolerance for
couch tracking should be assessed for different velocities and accelerations to define
a maximum tolerable speed. Motion sickness due to the tracking of the couch might
be an issue. Only very limited data exists on this topic [28, 120, 134].
All three motion detection systems detected the surface of the patient. This makes
our tracking approach a suitable tool for the tracking of breast or thoracic wall tu-
mors. However at the same time it is a limitation because motion of lung or liver
tumors cannot be tracked only based on surface detection systems. A correlation
model between internal and external motion, or an imaging modality which images
internal motion would be needed. Similarly for prostate or vertebral tumors, an
imaging technique, such as RF transponder localisation, MV or kV imaging dur-
ing treatment is needed to quantify intrafractional motion. The discussed imaging
modalities or a correlation model could be easily added to our existing couch tracking
system to make it more universal.
Chapter 8
Conclusions and future work
Precise Radiotherapy of hypo-fractionated treatments of moving tumors applied by
a linear accelerator was the topic of this PhD thesis. Hypofractionated radiotherapy
is currently an area of clinical research. Clinical trials are looking into giving higher
doses of radiation per fraction, but giving fewer fractions. The goal is to find out if
the tumor can be better controlled in this way or if the treatment time can be short-
ened with the same or better clinical outcome. However for moving tumors, large
safety margins need to be applied to cover the tumor volume with the full dose. This
leads to a large amount of healthy tissue being irradiated with high doses and even-
tually increases side effects. Therefore to safely apply hypofractionated treatments
to moving structures, motion management techniques are needed, to reduce safety
margins and high doses to healthy tissue. Two approaches to reduce intrafractional
motion to be able increase the dose per fraction are implemented and evaluated
within the frame of this thesis. First flattening filter free beams were implemented
for clinical use (Chapter3-5). Flattening filter free beams have an increased dose
rate (Chapter 3) compared to conventional beams, which leads to reduced treat-
ment times and reduced intrafractional motion as was shown in Chapter 6. The
use of flattening filter free beams has the potential to reduce patient motion as
well as prostate motion, however for periodic respiratory motion there is no benefit
expected. In Chapter 7 the reduction of safety margins for respiratory motion was
addressed. The compensation was performed by countersteering the respiratory mo-
tion with the treatment couch.
Below, results and conclusions from Chapter 3-7 will be discussed.
In Chapter 3 it was shown that air-vented ionization chambers can be reliably used
for relative dosimetry of flattening filter free beams. The Markus chamber demon-
strated the largest ion collection efficiency (0.994 @ DPP = 1.7 mGy, X10FFF
beam). The order of correction for reference dosimetry is given within Chapter 3.
However, liquid ionization chambers appear to be unsuitable for dosimetry in un-
flattened beams due to their decreased ion collection efficiency.
As a result of the planning study in Chapter 4 it was found that FFF beams re-
sulted in dose distributions similar to flattened beams. Additionally, it was shown
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that the mean body dose was a function of beam energy and decreased with increas-
ing mean beam energy. X10FFF beam provided the best solution, sparing rectum
and bladder and minimizing whole body dose. Moreover the planning study showed
that the number of MU increased for X6FFF and X10FFF by 7.7% and 1.2%. FFF
beams lead to a time efficient treatment delivery, particularly when combined with
hypofractionated VMAT.
In Chapter 5 the dosimetric accuracy of flattening filter free beam delivery for IMRT
and VMAT techniques was shown. Dose delivery was equally accurate for IMRT
and RA delivery as well as for the two beams evaluated. Additionally in the study
in Chapter 5 a set of QA devices suitable for use in high dose rate flattening filter
free beams was presented.
The study on the clinical application of FFF beams described in Chapter 6 showed
that SBRT using FFF beams is time efficient. Mean beam-on time was 1.6 min
and total treatment time 17.2 min. The high level of patient stability supported the
use of small ITV to PTV margins (in our case 6 mm), which benefit the patient by
potentially reducing toxicity.
In the last Chapter of the thesis (Chapter 7) the technical realisation of a couch track-
ing system was explained and the system was evaluated and characterized. Three
different motion detection sensors with different lag times were used and compared.
A lag time below 100 ms is needed to reliably track all possible breathing motion if
no prediction filters are used.
Interest in FFF technology with dose rates of up to 24 Gy/min is resulting from
the expectation that it will allow faster treatment delivery. This might lead to re-
duced intra-fractional motion of the patient. Additionally a reduced dose outside
the field is expected. Flattening filter free beams are clinically available since March
2010, since then over 40 scientific studies have been published on FFF technology.
Many clinics have already introduced FFF beams into the clinics, showing excellent
results concerning treatment efficiency and outcome [111, 87]. Within the frame of
this thesis four studies on FFF technology were performed, which are in line with
other publications showing the efficiency and safety of the FFF beams. Several other
publications have based their research on our findings on the safe delivery of FFF
beams.
Flattening filter free beams are mainly used for hypo-fractionated treatments [83,
95, 102]. Together with my colleagues I have performed two studies showing the
application of FFF beams for hypofractionated treatments of the prostate and the
lung (Chapter 4 and 6). Similar to Mancosu et al, Ong et al and Prendergast et al
[83, 95, 102], we have shown an increased treatment efficiency for both treatment
sites. For lung and liver patients this lead to excellent stability of the patient during
the treatment delivery (Chapter 6). However dosimterically we found only slight
improvements compared to treatments with flattened beams. This is in agreement
with the results of other researchers [123, 95].
The use of flattening filter free beams has the potential to reduce motion of the pa-
tient (Chapter 6) as well as prostate motion, however for periodic respiratory motion
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there is no benefit, as was recently shown by Ong et al [93]. This shows the need
of intra-fractional motion management. The three motion management techniques
currently used in clinical settings are motion encompassing treatment, gating and
tracking. In comparison to motion encompassing treatments, gating allows the treat-
ment to a smaller volume at the cost however of substantially increased treatment
time. The most sophisticated treatment technique appears to be tracking because it
confines the high dose to the tumor (small volume) and is time efficient. Within the
frame of my thesis a couch tracking system was developed which can compensate
for respiratory motion of the patient. The respiratory motion is detected by three
different surface detection systems. This makes it a suitable tool for tracking of
breast and thoracic wall tumors. However at the same time it is a limitation, be-
cause tumor motion of lung or liver tumors cannot be tracked only based on surface
detection systems. A correlation model between internal and external motion or in-
ternal motion imaging would be needed. Similarly for prostate or vertebral tumors,
MV or kV imaging during treatment is needed to quantify intra-fractional motion.
The discussed imaging modalities or a correlation model can be easily added to our
existing couch tracking system in order to make it more universal. In a next step,
patient tolerance concerning couch tracking should be assessed. Motion sickness due
to the tracking of the couch might be an issue. Only very limited data exists on
this topic [28, 120]. A large patient and volunteer study would be needed to address
the issue. Currently we are working on the implementation of prediction filters to
further reduce the residual motion during respiration and on a correlation model
to correlate the internal liver motion with the external motion. The field of intra-
fractional motion managment is large and many more PhD thesis will be needed to
satisfactorily cover all issues. However within the frame of this thesis two key issue
how intra-fractional motion can be managed were addressed.
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